



2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors

Phoebe F. Lamie & John N. Philoppes

To cite this article: Phoebe F. Lamie & John N. Philoppes (2020) 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors, Journal of Enzyme Inhibition and Medicinal Chemistry, 35:1, 864-879, DOI: [10.1080/14756366.2020.1740922](https://doi.org/10.1080/14756366.2020.1740922)

To link to this article: <https://doi.org/10.1080/14756366.2020.1740922>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



View supplementary material [↗](#)



Published online: 25 Mar 2020.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)

RESEARCH PAPER



2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors


Phoebe F. Lamie and John N. Philoppes

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

ABSTRACT

A novel 2-thiopyrimidine/chalcone hybrid was designed, synthesised, and evaluated for their cytotoxic activities against three different cell lines, K-562, MCF-7, and HT-29. The most active cytotoxic derivatives were **9d**, **9f**, **9n**, and **9p** (IC_{50} =0.77–1.74 μ M, against K-562 cell line), **9a** and **9r** (IC_{50} =1.37–3.56 μ M against MCF-7 cell line), and **9a**, **9l**, and **9n** (IC_{50} =2.10 and 2.37 μ M against HT-29 cell line). Compounds **9a**, **9d**, **9f**, **9n**, and **9r** were further evaluated for their cytotoxicity against normal fibroblast cell line WI38. Moreover, STAT3 and STAT5a inhibitory activities were determined for the most active derivatives **9a**, **9d**, **9f**, **9n**, and **9r**. Dual inhibitory activity was observed in compound **9n** (IC_{50} =113.31 and 50.75 μ M, against STAT3 and STAT5a, respectively). Prediction of physicochemical properties, drug likeness score, pharmacokinetic and toxic properties was detected.

GRAPHICAL ABSTRACT



ARTICLE HISTORY

Received 11 January 2020
Revised 2 March 2020
Accepted 2 March 2020

KEYWORDS

2-Thiopyrimidine; chalcone; STAT; cytotoxicity; computational analysis

Introduction

One of the main causes of mortality all over the world is cancer^{1,2}. The highest prevalence for cancer death is being for stomach, breast, prostatic, lung, and colon³.

The most common female cancer around the world is breast cancer. It represents for 16% of all female cancers and 18.2% of all cancer death causes including both males and females⁴.

On the other hand, about two million new cases are diagnosed every year for colorectal cancer. Thus, making it as one of the most common causes of cancer-related death^{5,6}.

Another common cause of cancer death is leukaemia, cancer in blood-forming cells of the bone marrow, which is chemoresistant^{7–11}. Although, treatment of cancer using chemotherapeutic agents is still used for several cancer types including breast, colon and leukaemia cancers, high toxicity level of chemotherapeutic drugs limit their use¹².


A critical signalling intermediate in cancer cells, specially leukaemia, breast and colon cancer cells is called signal transducer and activator of transcription (STAT) protein family^{13–17}.

They are cytoplasmic transcription factors. STAT family consists of seven members, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. STAT2, STAT4, and STAT6 are responsible for regulation of immune response. While, STAT1, STAT3, and STAT5 can control cell cycle (cyclin D1, D2, c-Myc), cell survival (Bcl-xl, Bcl2, Mcl-1), and angiogenesis (HIF1 α , VEGFR) through regulation of gene expression^{18,19}.

STAT can be activated either by receptor tyrosin kinases like JAKs, PDGFR, EGFR, and FLT3, or through non-receptor tyrosinases, Src, Brk, and Bcr-Abl. Also, activation of STAT may be from activation of cytokines (IL-6), growth factors or negative feedback mechanisms^{20–24}.

Phosphorylation of STATs transforms them to active form causing their homo- or heterodimerisation then migration to the

CONTACT Phoebe F. Lamie  feebi.lamey@pharm.bsu.edu.eg;  feby.farag@yahoo.com  Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt

 Supplemental data for this article can be accessed [here](#).

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

nucleus to control gene expression. Over activation of STAT level can lead to tumorigenesis²⁰.

Several studies have demonstrated that blocking STAT3 or STAT5 signalling pathway led to apoptosis in tumour cells. While, normal cells were able to survive even under a very low concentration of STAT3 or STAT5 and also capable of growing using other mechanisms^{21,25}.

Therefore, development of new anti-cancer agents with less toxicity and overcoming chemotherapeutic drug resistance can be achieved by: (1) using drugs that target two or three activators of STAT3²⁴ or (2) combined targeting of STAT3 and STAT5⁸.

It was found that a potent STAT3 inhibitor, S31-201 (**I**, Figure 1), could inhibit proliferation of hepatocellular and breast carcinoma in mice¹⁶.

Moreover, compound S31-201.1066 (**II**, Figure 1), containing sulphonamide group could inhibit STAT3 function in both breast and myeloma cancer cells (EC_{50} =10 and 16 μ M, respectively)²⁶. Another compound, curcumine analogue, FLLL32 (**III**, Figure 1), showed potent inhibitory activity in many human cancer cell lines such as breast, colorectal, melanoma, and myeloma by preventing STAT3 dimerisation and downstream functioning^{20,27}.

Moreover, treatment with chalcone **IV** (Figure 1) caused significant decrease in STAT3 level in leukaemia HL-60 cell line²⁸.

Pyrazolo[1,5-*a*]pyrimidine/chalcone hybrid **V** (Figure 1) showed promising anti-proliferative activity by down regulation of STAT3 in MDA-MB-231 cells²⁹.

Additionally, NCI library identified two compounds (**BP-1108** and **BP-1075**) as the most potent STAT5 in K562 leukaemia cell lines through down regulation of STATs-defendant genes³⁰.

In medicinal chemistry, a very well-known heterocycle is pyrimidine. It takes its importance from its presence in thymidine, cytosine and uracil bases, the building blocks of DNA and RNA nucleic acids^{31,32}.

2-Thiopyrimidines (2-TPs), also named as 2-mercaptopyrimidines, are one of the most important class of pyrimidines.

They attract the biochemists attention due to their wide range of applications in preparation of cardiotonic drugs, antitubercular and anti-inflammatory agents^{33,34}.

Moreover, 2-TPs were evaluated for their anticancer activity³³. They were reported to have potent antitumor activity against leukaemia, colon and breast cell lines such as compounds **VI-IX** (Figure 1)³⁵⁻³⁸.

Synthesis of 2-TPs derivatives could be achieved from reaction of chalcone derivatives with thiourea³⁹. As chalcones constitute an important group of natural products, their biological activities were arisen from their chemical structure, α,β -unsaturated carbonyl group⁴⁰.

Many synthesised chalcones were reported to have potent *in vitro* anticancer activity against human colon carcinoma, non-small cell lung carcinoma, and breast cancer⁴¹⁻⁴⁴.

Thus, both chloro- and dimethylamino-derivatives of compound **X** (Figure 1), showed cytotoxic activity against human leukaemia cells with CC_{50} =2.17 and 2.06 μ M, respectively⁴⁰. While, compound **XI** (Figure 1) was apoptosis inducer in A549 cells⁴⁵.

In light of the above facts, and as a part of our previously published anticancer research articles^{46,47}, our scope in this research was to design and synthesised a new series of 2-TP/chalcone hybrids (Figure 1), through molecular hybridisation, by merging:

(i) 2-Thiopyrimidine scaffold, such as in compounds (**VI-IX**), (ii) chalcone part from compounds (**III-V**, **X**, **XI**), (iii) choosing substituents on phenyl rings of pyrimidine C-4, pyrimidine C-6, and chalcone as in compounds (**I-V**), and (iv) amide linkage to mimic that in compounds (**I**, **II**, **VI**, **X**, **XI**). The cytotoxic activities of the

synthesised derivatives were evaluated against leukaemia (K-562), breast (MCF-7), and colon (HT-29) cancer cell lines. Inhibitory activities of the most potent bioactive molecules against STAT3 and STAT5a were measured, aiming at finding more effective anti-cancer therapeutics.

Experimental

Chemistry

Melting points were measured on the Griffin apparatus and were uncorrected. Determination of IR spectra was achieved using Shimadzu IR-435 spectrophotometer with KBr discs and values were obtained in cm^{-1} . 1H NMR and ^{13}C NMR were recorded on Bruker instrument at 400 MHz for 1H NMR and 100 MHz for ^{13}C NMR spectrophotometer (Faculty of Pharmacy, Mansoura University, Mansoura, Egypt), in DMSO- d_6 (as a solvent), D_2O using TMS as an internal standard and chemical shifts (δ) were expressed in parts per million (ppm) compared to internal standard, TMS (δ =0 ppm). Coupling constant (*J*) values were expressed in Hertz (Hz). Signal splitting patterns were designated as follows: s, singlet; d, doublet, t, triplet; q, quartette; m, multiplet. The electron impact (EI) mass spectra were carried out using Hewlett Packard 5988 spectrometer (Palo Alto, CA) at Faculty of Science, Cairo University, Giza, Egypt. Microanalysis was calculated for C, H, N on Perkin-Elmer 2400 at the Microanalytical centre, Faculty of Science, Cairo University, Egypt and was within $\pm 0.4\%$ of theoretical values. The progress of the reaction and purity of products were monitored by thin layer chromatography (TLC), pre-coated plastic sheets, 0.2 mm silica gel with UV indicator (Macherey-Nagel, Düren, Germany). All used reagents and solvents were purchased from the Aldrich Chemical Company (Milwaukee, WI).

General method for preparation of compounds 4a-f

A mixture of the appropriate chalcone derivative **3a-f** (0.01 mol), thiourea (0.76 g, 0.01 mol), and KOH (0.11 g, 0.02 mol) in absolute ethanol (20 ml) was heated under reflux temperature for 12 h. The resulting solution was evaporated to dryness or (a precipitate in case of **3c** and **3f**). The obtained residue was solubilised in water, filtered and dried. The crude product was crystallised from ethanol/DMF (8:2) to get compounds **4a-f**.

4-(4-Methoxyphenyl)-6-*p*-tolylpyrimidine-2-thiol (4a). Yield 82%; yellow powder; (ethanol 95%); mp 149–151 °C; IR (cm^{-1}): 3413 (NH), 3192 (CH aromatic), 2958 (CH aliphatic); 1H NMR (400 MHz, DMSO- d_6) δ 2.50 (s, 3H, CH_3), 4.43 (s, 3H, OCH_3), 7.24–7.59 (m, 4H, *p*-methoxyphenyl H-3, H-5, *p*-tolyl H-3, H-5), 7.79–7.91 (m, 4H, pyrimidine H-5, *p*-methoxyphenyl H-2, H-6, NH, D_2O exchangeable), 8.21 (d, *J*= 8.4 Hz, 2H, *p*-tolyl H-2, H-6); ^{13}C NMR (100 MHz, DMSO- d_6) δ 21.2 (CH_3), 55.6 (OCH_3), 101.0 (pyrimidine C-5), 114.7 (*p*-methoxyphenyl C-3, C-5), 126.1 (*p*-tolyl C-2, C-6), 128.1 (*p*-tolyl C-3, C-5), 129.4 (*p*-methoxyphenyl C-2, C-6), 130.9 (*p*-methoxyphenyl C-1), 134.5 (*p*-tolyl C-1), 136.7 (*p*-tolyl C-4), 159.2 (*p*-methoxyphenyl C-4), 164.6 (pyrimidine C-4) 172.9 (pyrimidine C-6), 175.2 (pyrimidine C-2); EIMS (*m/z*): 309.00 (*M* + 1, 31.75%), 308.00 (*M*⁺, 74.33%), 307.00 (100%); Anal. Calcd. for $C_{18}H_{16}N_2OS$ (308.40): C, 70.10; H, 5.23; N, 9.08. Found: C, 70.31; H, 5.07; N, 8.88.

4-(4-Methoxyphenyl)-6-(4-nitrophenyl)pyrimidine-2-thiol (4b). Yield 75%; yellow crystals; mp 63–65 °C³⁹.




Figure 1. The designed strategy for 2-TP/chalcone hybrids as new anticancer STAT inhibitors.

4-[4-(2-Chloroethoxy)phenyl]-6-(4-methoxyphenyl)pyrimidine-2-thiol (4c). Yield 69%; yellow powder; (ethanol 95%); mp 282–284 °C; IR (cm⁻¹): 3436 (NH), 3192 (CH aromatic), 2927 (CH aliphatic); ¹H NMR (400 MHz, DMSO-d₆) δ 3.83–4.37 (m, 7H, OCH₃, OCH₂, CH₂Cl), 6.96–7.10 (m, 7H, *p*-chloroethoxyphenyl H-2, H-3, H-

5, H-6, *p*-methoxyphenyl H-3, H-5, NH, D₂O exchangeable), 8.22–8.30 (m, 3H, *p*-methoxyphenyl H-2, H-6, pyrimidine H-5); ¹³C NMR (100 MHz, DMSO-d₆) δ 42.9 (CH₂Cl), 55.8 (OCH₃), 68.1 (OCH₂), 105.0 (pyrimidine C-5), 114.8 (*p*-methoxyphenyl C-3, C-5), 115.4 (*p*-chloroethoxyphenyl C-3, C-5), 121.8 (*p*-chlorophenyl C-2, C-6),

127.9 (*p*-methoxyphenyl C-1), 128.5 (*p*-methoxyphenyl C-2, C-6), 129.4 (*p*-chloroethoxyphenyl C-2, C-6), 130.0 (*p*-chloroethoxyphenyl C-1), 160.6 (*p*-methoxyphenyl C-4), 161.7 (*p*-chloroethoxyphenyl C-4), 162.5 (pyrimidine C-4) 176.1 (pyrimidine C-6), 179.3 (pyrimidine C-2); Anal. Calcd. for $C_{19}H_{17}ClN_2O_2S$ (372.87): C, 61.20; H, 4.60; N, 7.51. Found: C, 61.41; H, 4.57; N, 7.75.

4-(4-Chlorophenyl)-6-*p*-tolylpyrimidine-2-thiol (4d). Yield 91%; yellow crystals; mp 180–182 °C⁴⁷.

4-(4-Chlorophenyl)-6-(4-nitrophenyl)pyrimidine-2-thiol (4e). Yield 65%; yellow powder; (ethanol 95%); mp 263–265 °C; IR (cm⁻¹): 3434 (NH), 3064 (CH aromatic); ¹H NMR (400 MHz, DMSO-d₆) δ 7.60 (d, *J* = 8.4 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.96 (s, 1H, NH, D₂O exchangeable), 8.33–8.34 (m, 4H, *p*-chlorophenyl H-2, H-6, *p*-nitrophenyl H-2, H-6), 8.54 (d, *J* = 8.4 Hz, 2H, *p*-nitrophenyl H-3, H-5), 8.66 (s, 1H, pyrimidine H-5); ¹³C NMR (100 MHz, DMSO-d₆) δ 101.3 (pyrimidine C-5), 123.6 (*p*-chlorophenyl C-2, C-6), 128.0 (*p*-nitrophenyl C-3, C-5), 128.9 (*p*-chlorophenyl C-1), 129.3 (*p*-chlorophenyl C-3, C-5), 129.5 (*p*-nitrophenyl C-2, C-6), 133.5 (*p*-chlorophenyl C-4), 139.2 (*p*-nitrophenyl C-1), 150.2 (*p*-nitrophenyl C-4), 164.6 (pyrimidine C-4) 176.3 (pyrimidine C-6), 180.4 (pyrimidine C-2); Anal. Calcd. for $C_{16}H_{10}ClN_3O_2S$ (343.79): C, 55.90; H, 2.93; N, 12.22. Found: C, 60.12; H, 2.87; N, 12.46.

4-[4-(2-Chloroethoxy)phenyl]-6-(4-chlorophenyl)pyrimidine-2-thiol (4f). Yield 62%; yellow powder; (ethanol 95%); mp 242–244 °C; IR (cm⁻¹): 3417 (NH), 3066 (CH aromatic), 2927 (CH aliphatic); ¹H NMR (400 MHz, DMSO-d₆) δ 3.98 (t, *J* = 8.4 Hz, 2H, CH₂Cl), 4.36 (t, *J* = 8.4 Hz, 2H, OCH₂), 7.07–7.12 (m, 4H, *p*-chloroethoxyphenyl H-3, H-5, *p*-chlorophenyl H-2, H-6), 7.31 (s, 1H, NH, D₂O exchangeable), 7.60 (d, *J* = 8.4 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.96 (s, 1H, pyrimidine H-5), 8.31 (d, *J* = 8.4 Hz, 2H, *p*-chloroethoxyphenyl H-2, H-6); ¹³C NMR (100 MHz, DMSO-d₆) δ 43.4 (CH₂Cl), 68.5 (OCH₂), 103.9 (pyrimidine C-5), 115.3 (*p*-chloroethoxyphenyl C-3, C-5), 120.2 (*p*-chlorophenyl C-2, C-6), 128.5 (*p*-chlorophenyl C-1), 129.4 (*p*-chloroethoxyphenyl C-2, C-6), 129.5 (*p*-chlorophenyl C-3, C-5), 130.7 (*p*-chloroethoxyphenyl C-1), 136.6 (*p*-chlorophenyl C-4), 161.7 (*p*-chloroethoxyphenyl C-4), 162.8 (pyrimidine C-4) 176.3 (pyrimidine C-6), 179.0 (pyrimidine C-2); EIMS (*m/z*): 376.95 (*M* + 1, 16.83%), 375.90 (*M*⁺, 19.31%), 55.10 (100%); Anal. Calcd. for $C_{18}H_{14}ClN_2OS$ (377.29): C, 57.30; H, 3.74; N, 7.42. Found: C, 57.41; H, 3.57; N, 7.68.

General method for preparation of compounds 9a–r

A mixture of pyrimidine derivatives **4a–f** (0.01 mol), acetyl chloride derivatives **8a–c** (0.01 mol), and catalytic amount of TEA is stirred in acetonitrile (20 ml) for 24 h. The solution was evaporated to dryness. The obtained residue was solubilised in ice cold water and neutralised with conc. HCl. The obtained solid was filtered, dried and crystallised from ethanol/DMF (8:2).

(ZE)-2-[4-(4-Methoxyphenyl)-6-*p*-tolylpyrimidin-2-ylthio]-N-[4-[3-(4-methoxyphenyl)acryloyl]phenyl]acetamide (9a). Yield 82%; yellow powder; mp 226–228 °C; IR (cm⁻¹): 3257 (NH), 3039 (CH aromatic), 2925 (CH aliphatic), 1795, 1663 (2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 1.86 (s, 3H, CH₃), 4.41 (s, 3H, OCH₃), 4.43 (s, 3H, OCH₃), 4.84 (s, 2H, CH₂), 6.67 (d, *J* = 8.4 Hz, 2H, *p*-methoxyphenylacryloyl H-3, H-5), 7.10 (d, *J* = 7.6 Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.24 (d, *J* = 8.4 Hz, 2H, *p*-methoxyphenylacryloyl H-2, H-6), 7.33 (d, *J* = 6.0 Hz, 2H, *p*-tolyl H-3, H-5), 7.44–7.74 (m, 7H, COCH=CH, pyrimidine H-5, *p*-methoxyphenyl H-2, H-6, *p*-tolyl H-2, H-6),

7.91–7.94 (m, 4H, phenyl H-2, H-3, H-5, H-6), 10.84 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 22.3 (CH₃), 36.2 (CH₂), 56.4 (2OCH₃), 113.7 (*p*-methoxyphenylacryloyl C-3, C-5), 118.8 (*p*-methoxyphenyl C-3, C-5), 120.1 (COCH=CH), 121.7 (phenyl C-2, C-6), 127.5 (*p*-methoxyphenylacryloyl C-1), 127.6 (*p*-tolyl C-2, C-6), 129.0 (*p*-methoxyphenyl C-2, C-6), 129.1 (*p*-methoxyphenyl C-1), 130.2 (*p*-tolyl C-3, C-5), 130.8 (*p*-methoxyphenylacryloyl C-2, C-6), 131.4 (phenyl C-3, C-5), 132.0 (*p*-tolyl C-4), 133.5 (phenyl C-4), 136.9 (*p*-tolyl C-1), 144.3 (phenyl C-1), 154.4 (COCH=CH), 155.1 (*p*-methoxyphenylacryloyl C-4), 155.4 (*p*-methoxyphenyl C-4), 164.1 (pyrimidine C-6), 167.8 (pyrimidine C-4), 172.3 (pyrimidine C-2), 173.0 (CONH), 190.0 (CO); Anal. Calcd. for $C_{36}H_{31}N_3O_4S$ (601.20): C, 71.86; H, 5.19; N, 6.98. Found: C, 71.67; H, 5.07; N, 6.93.

(ZE)-N-[4-[3-(3,4-Dimethoxyphenyl)acryloyl]phenyl]-2-[4-(4-methoxyphenyl)-6-*p*-tolylpyrimidin-2-ylthio]acetamide (9b). Yield 65%; yellow powder; mp 165–167 °C; IR (cm⁻¹): 3324 (NH), 3061 (CH aromatic), 2925 (CH aliphatic), 1663 (broad, 2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 2.36 (s, 3H, CH₃), 3.81 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 3.86 (s, 3H, OCH₃), 4.23 (s, 2H, CH₂), 6.97 (d, *J* = 8.4 Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.03 (d, *J* = 8.0 Hz, 1H, dimethoxyphenyl H-5), 7.28 (d, *J* = 8.0 Hz, 1H, dimethoxyphenyl H-6), 7.37 (d, *J* = 12.0 Hz, 1H, COCH=CH), 7.54 (s, 1H, dimethoxyphenyl H-2), 7.69 (d, *J* = 12.0 Hz, 1H, COCH=CH), 7.83–7.87 (m, 3H, *p*-tolyl H-3, H-5, pyridine H-5), 8.18–8.23 (m, 6H, phenyl H-2, H-6, *p*-methoxyphenyl H-2, H-6, *p*-tolyl H-2, H-6), 8.31 (d, *J* = 8.4 Hz, 2H, phenyl H-3, H-5), 10.84 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 21.4 (CH₃), 36.4 (CH₂), 55.8 (OCH₃), 56.0 (OCH₃), 56.1 (OCH₃), 107.4 (pyrimidine C-5), 111.0 (dimethoxyphenyl C-2), 111.9 (dimethoxyphenyl C-5), 114.6 (dimethoxyphenyl C-6), 118.8 (*p*-methoxyphenyl C-3, C-5), 119.8 (COCH=CH), 124.4 (phenyl C-2, C-6), 127.7 (*p*-tolyl C-2, C-6), 128.0 (*p*-methoxyphenyl C-2, C-6), 129.6 (*p*-methoxyphenyl C-1), 130.3 (*p*-tolyl C-3, C-5), 130.4 (*p*-tolyl C-1), 133.0 (dimethoxyphenyl C-1), 133.6 (phenyl C-3, C-5), 141.7 (*p*-tolyl C-4), 143.9 (phenyl C-4), 144.4 (phenyl C-1), 149.4 (dimethoxyphenyl C-3), 150.0 (dimethoxyphenyl C-4), 151.6 (COCH=CH), 162.3 (*p*-methoxyphenyl C-4), 164.2 (pyrimidine C-6), 164.3 (pyrimidine C-4), 167.7 (pyrimidine C-2), 170.8 (CONH), 187.8 (CO); Anal. Calcd. for $C_{37}H_{33}N_3O_5S$ (631.21): C, 70.34; H, 5.27; N, 6.65. Found: C, 70.54; H, 5.07; N, 6.71.

(ZE)-2-[4-(4-Methoxyphenyl)-6-*p*-tolylpyrimidin-2-ylthio]-N-[4-[3-(3,4,5-trimethoxyphenyl)acryloyl]phenyl]acetamide (9c). Yield 56%; yellow powder; mp 195–197 °C; IR (cm⁻¹): 3290 (NH), 2998 (CH aromatic), 2927 (CH aliphatic), 1665 (broad, 2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 2.36 (s, 3H, CH₃), 3.72 (s, 3H, OCH₃), 3.81 (s, 3H, OCH₃), 3.87 (s, 6H, 2OCH₃), 4.24 (s, 2H, CH₂), 6.95 (s, 2H, trimethoxyphenyl H-2, H-6), 6.98–7.28 (m, 4H, *p*-methoxyphenyl H-3, H-5, *p*-tolyl H-3, H-5), 7.69 (d, *J* = 12.0 Hz, 1H, COCH=CH), 7.87–8.19 (m, 3H, COCH=CH, *p*-tolyl H-2, H-6), 8.22–8.31 (m, 7H, *p*-methoxyphenyl H-2, H-6, pyrimidine H-5, phenyl H-2, H-3, H-5, H-6), 10.86 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 21.4 (CH₃), 36.4 (CH₂), 55.8 (OCH₃), 56.5 (2OCH₃), 60.6 (OCH₃), 106.8 (trimethoxyphenyl C-2, C-6), 107.4 (pyrimidine C-5), 114.5 (*p*-methoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 121.5 (COCH=CH), 126.9 (*p*-tolyl C-2, C-6), 127.7 (trimethoxyphenyl C-1), 128.5 (*p*-methoxyphenyl C-1), 129.6 (*p*-methoxyphenyl C-2, C-6), 130.4 (*p*-tolyl C-3, C-5), 131.0 (*p*-tolyl C-4), 132.8 (phenyl C-3, C-5), 133.5 (*p*-tolyl C-1), 140.0 (phenyl C-4), 141.7 (trimethoxyphenyl C-4), 144.0 (phenyl C-1), 144.4 (COCH=CH), 153.5 (trimethoxyphenyl C-3, C-5), 162.3 (*p*-methoxyphenyl C-4), 164.2 (pyrimidine C-6), 164.3 (pyrimidine C-4), 167.7 (pyrimidine C-2), 170.7 (CONH), 187.9 (CO); EIMS (*m/z*): 662.05 (*M* + 1, 5.50%), 661.05 (*M*⁺, 12.94%),

322.05 (100%); Anal. Calcd. for $C_{38}H_{35}N_3O_6S$ (661.22): C, 68.97; H, 5.33; N, 6.35. Found: C, 68.78; H, 5.17; N, 6.24.

(ZE)-2-[4-(4-Methoxyphenyl)-6-(4-nitrophenyl)pyrimidin-2-ylthio]-N-{4-[3-(4-methoxyphenyl)acryloyl]phenyl}acetamide (9d). Yield 57%; yellow powder; mp 183–185 °C; IR (cm^{-1}): 3407 (NH), 3063 (CH aromatic), 2930 (CH aliphatic), 1664 (broad, $2C=O$); 1H NMR (400 MHz, DMSO- d_6) δ 3.83 (s, 3H, OCH_3), 3.84 (s, 3H, OCH_3), 4.24 (s, 2H, CH_2), 6.98 (d, $J = 8.8$ Hz, 2H, *p*-methoxyphenylacryloyl H-3, H-5), 7.03 (d, $J = 8.8$ Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.69 (d, $J = 15.6$ Hz, 1H, $COCH=CH$), 7.80–7.86 (m, 5H, $COCH=CH$, *p*-methoxyphenylacryloyl H-2, H-6, *p*-methoxyphenyl H-2, H-6), 8.18 (d, $J = 8.8$ Hz, 2H, phenyl H-2, H-6), 8.27 (d, $J = 8.8$ Hz, 2H, phenyl H-3, H-5), 8.33 (d, $J = 8.8$ Hz, 2H, *p*-nitrophenyl H-2, H-6), 8.40 (s, 1H, pyrimidine H-5), 8.56 (d, $J = 8.8$ Hz, 2H, *p*-nitrophenyl H-3, H-5), 10.86 (s, 1H, NH, D_2O exchangeable); ^{13}C NMR (100 MHz, DMSO- d_6) δ 36.4 (CH_2), 55.8 (OCH_3), 55.9 (OCH_3), 109.1 (pyrimidine C-5), 114.7 (*p*-methoxyphenylacryloyl C-3, C-5), 114.8 (*p*-methoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 119.8 (*p*-nitrophenyl C-3, C-5), 124.2 ($COCH=CH$), 127.8 (*p*-nitrophenyl C-2, C-6), 128.2 (*p*-methoxyphenyl C-2, C-6), 129.1 (*p*-methoxyphenylacryloyl C-1), 129.8 (*p*-methoxyphenyl C-1), 130.0 (*p*-methoxyphenylacryloyl C-2, C-6), 130.3 (phenyl C-3, C-5), 131.1 (*p*-nitrophenyl C-1), 133.1 (phenyl C-4), 142.4 (phenyl C-1), 143.8 ($COCH=CH$), 149.3 (*p*-nitrophenyl C-4), 161.7 (*p*-methoxyphenylacryloyl C-4), 162.2 (*p*-methoxyphenyl C-4), 162.6 (pyrimidine C-6), 164.9 (pyrimidine C-4), 167.6 (pyrimidine C-2), 171.3 (CONH), 187.8 (CO); Anal. Calcd. for $C_{35}H_{28}N_4O_6S$ (632.17): C, 66.44; H, 4.46; N, 8.86. Found: C, 66.42; H, 4.39; N, 8.74.

(ZE)-N-{4-[3-(3,4-Dimethoxyphenyl)acryloyl]phenyl}-2-[4-(4-methoxyphenyl)-6-(4-nitrophenyl)pyrimidin-2-ylthio]-acetamide (9e). Yield 54%; yellow powder; mp 225–227 °C; IR (cm^{-1}): 3431 (NH), 3039 (CH aromatic), 2924 (CH aliphatic), 1656 (broad, $2C=O$); 1H NMR (400 MHz, DMSO- d_6) δ 3.83 (s, 3H, OCH_3), 3.87 (s, 6H, $2OCH_3$), 4.27 (s, 2H, CH_2), 6.99 (d, $J = 8.4$ Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.03 (d, $J = 8.8$ Hz, 1H, dimethoxyphenyl H-5), 7.39 (d, $J = 8.8$ Hz, 1H, dimethoxyphenyl H-6), 7.55 (s, 1H, dimethoxyphenyl H-2), 7.68 (d, $J = 15.2$ Hz, 1H, $COCH=CH$), 7.82–7.88 (m, 3H, $COCH=CH$, *p*-methoxyphenyl H-2, H-6), 8.20 (d, $J = 8.8$ Hz, 2H, phenyl H-2, H-6), 8.28 (d, $J = 8.8$ Hz, 2H, phenyl H-3, H-5), 8.34 (d, $J = 8.8$ Hz, 2H, *p*-nitrophenyl H-2, H-6), 8.41 (s, 1H, pyrimidine H-5), 8.57 (d, $J = 8.8$ Hz, 2H, *p*-nitrophenyl H-3, H-5), 10.87 (s, 1H, NH, D_2O exchangeable); ^{13}C NMR (100 MHz, DMSO- d_6) δ 36.4 (CH_2), 55.9 (OCH_3), 56.0 (OCH_3), 56.2 (OCH_3), 109.1 (pyrimidine C-5), 111.0 (dimethoxyphenyl C-2), 112.0 (dimethoxyphenyl C-5), 114.7 (*p*-methoxyphenyl C-3, C-5), 118.8 (dimethoxyphenyl C-6), 119.8 (phenyl C-2, C-6), 124.2 (*p*-nitrophenyl C-3, C-5), 124.4 ($COCH=CH$), 128.0 (*p*-nitrophenyl C-2, C-6), 128.2 (*p*-methoxyphenyl C-2, C-6), 129.1 (dimethoxyphenyl C-1), 129.8 (*p*-methoxyphenyl C-1), 130.3 (phenyl C-3, C-5), 132.0 (phenyl C-4), 142.4 (phenyl C-1), 143.8 (*p*-nitrophenyl C-1), 144.4 ($COCH=CH$), 149.4 (dimethoxyphenyl C-4), 149.4 (dimethoxyphenyl C-3), 153.5 (*p*-nitrophenyl C-4), 162.2 (*p*-methoxyphenyl C-4), 162.6 (pyrimidine C-6), 165.0 (pyrimidine C-4), 167.6 (pyrimidine C-2), 171.3 (CONH), 187.8 (CO); Anal. Calcd. for $C_{36}H_{30}N_4O_7S$ (662.18): C, 65.24; H, 4.56; N, 8.45. Found: C, 65.35; H, 4.71; N, 8.24.

(ZE)-2-[4-(4-Methoxyphenyl)-6-(4-nitrophenyl)pyrimidin-2-ylthio]-N-{4-[3-(3,4,5-trimethoxyphenyl)acryloyl]phenyl}acetamide (9f). Yield 69%; yellow powder; mp 254–256 °C; IR (cm^{-1}): 3265 (NH), 3103 (CH aromatic), 2933 (CH aliphatic), 1663 (broad, $2C=O$); 1H NMR (400 MHz, DMSO- d_6) δ 3.71 (s, 3H, OCH_3), 3.82 (s, 3H, OCH_3),

3.87 (s, 6H, $2OCH_3$), 4.27 (s, 2H, CH_2), 6.98 (d, $J = 8.0$ Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.23 (s, 2H, trimethoxyphenyl H-2, H-6), 7.69 (d, $J = 12.0$ Hz, 1H, $COCH=CH$), 7.86–7.92 (m, 3H, $COCH=CH$, *p*-methoxyphenyl H-2, H-6), 8.21 (d, $J = 8.0$ Hz, 2H, phenyl H-2, H-6), 8.27 (d, $J = 8.0$ Hz, 2H, phenyl H-3, H-5), 8.33 (d, $J = 8.0$ Hz, 2H, *p*-nitrophenyl H-2, H-6), 8.40 (s, 1H, pyrimidin H-5), 8.56 (d, $J = 8.0$ Hz, 2H, *p*-nitrophenyl H-3, H-5), 10.89 (s, 1H, NH, D_2O exchangeable); ^{13}C NMR (100 MHz, DMSO- d_6) δ 36.4 (CH_2), 55.8 (OCH_3), 56.5 ($2OCH_3$), 60.6 (OCH_3), 106.8 (trimethoxyphenyl C-2, C-6), 109.0 (pyrimidine C-5), 114.6 (*p*-methoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 121.4 ($COCH=CH$), 124.2 (*p*-nitrophenyl C-3, C-5), 128.1 (trimethoxyphenyl C-1), 129.1 (*p*-nitrophenyl C-2, C-6), 129.8 (*p*-methoxyphenyl C-2, C-6), 130.4 (phenyl C-3, C-5), 130.7 (*p*-methoxyphenyl C-1), 132.9 (phenyl C-4), 140.0 (trimethoxyphenyl C-4), 142.3 (*p*-nitrophenyl C-1), 144.3 (phenyl C-1), 144.4 ($COCH=CH$), 149.3 (*p*-nitrophenyl C-4), 153.5 (trimethoxyphenyl C-3, C-5), 162.2 (*p*-methoxyphenyl C-4), 162.6 (pyrimidine C-6), 164.9 (pyrimidine C-4), 167.6 (pyrimidine C-2), 171.3 (CONH), 187.9 (CO); EIMS (m/z): 693.00 ($M+1$, 0.93%), 692.00 (M^+ , 1.33%), 55.10 (100%); Anal. Calcd. for $C_{37}H_{32}N_4O_8S$ (692.19): C, 64.15; H, 4.66; N, 8.09. Found: C, 63.98; H, 4.57; N, 7.89.

(ZE)-2-[4-[4-(2-Chloroethoxy)phenyl]-6-(4-methoxyphenyl)pyrimidin-2-ylthio]-N-{4-[3-(4-methoxyphenyl)acryloyl]phenyl}acetamide (9g). Yield 52%; yellow powder; mp 280–282 °C; IR (cm^{-1}): 3431 (NH), 3039 (CH aromatic), 2935 (CH aliphatic), 1598 (broad, $2C=O$); 1H NMR (400 MHz, DMSO- d_6) δ 3.70 (s, 3H, OCH_3), 3.83–3.85 (m, 5H, OCH_3 and CH_2Cl), 4.21–4.23 (m, 4H, OCH_2 and CH_2), 7.02–7.16 (m, 6H, *p*-methoxyphenyl H-3, H-5, *p*-methoxyphenylacryloyl H-3, H-5 and *p*-chloroethoxyphenyl H-3, H-5), 7.71–7.96 (m, 9H, *p*-methoxyphenyl H-2, H-6, *p*-methoxyphenylacryloyl H-2, H-6, *p*-chloroethoxyphenyl H-2, H-6, phenyl H-2, H-6 and $COCH=CH$), 8.16 (d, $J = 8.4$ Hz, 2H, phenyl H-3, H-5), 8.18–8.20 (m, 2H, pyrimidin H-5 and $COCH=CH$), 10.89 (s, 1H, NH, D_2O exchangeable); ^{13}C NMR (100 MHz, DMSO- d_6) δ 36.2 (CH_2), 40.6 (CH_2Cl), 55.4 (OCH_3), 55.8 (OCH_3), 68.9 (OCH_2), 107.8 (pyrimidine C-5), 114.1 (*p*-methoxyphenylacryloyl C-3, C-5), 114.7 (*p*-methoxyphenyl C-3, C-5), 114.8 (*p*-chloroethoxyphenyl C-3, C-5), 121.3 ($COCH=CH$), 122.1 (phenyl C-2, C-6), 127.4 (*p*-chloroethoxyphenyl C-1), 127.5 (*p*-methoxyphenylacryloyl C-1), 128.3 (*p*-chloroethoxyphenyl C-2, C-6), 129.5 (*p*-methoxyphenyl C-2, C-6), 130.3 (*p*-methoxyphenylacryloyl C-2, C-6), 131.1 (phenyl C-3, C-5), 133.5 (phenyl C-4), 144.0 (phenyl C-1), 144.3 (*p*-methoxyphenyl C-1), 145.4 ($COCH=CH$), 159.3 (*p*-chloroethoxyphenyl C-4), 159.8 (*p*-methoxyphenylacryloyl C-4), 160.6 (*p*-methoxyphenyl C-4), 162.8 (pyrimidine C-6), 164.9 (pyrimidine C-4), 168.6 (pyrimidine C-2), 172.3 (CONH), 189.9 (CO); Anal. Calcd. for $C_{37}H_{32}ClN_4O_5S$ (665.18): C, 66.71; H, 4.84; N, 6.31. Found: C, 66.98; H, 4.57; N, 6.28.

(ZE)-2-[4-[4-(2-Chloroethoxy)phenyl]-6-(4-methoxyphenyl)pyrimidin-2-ylthio]-N-{4-[3-(3,4-dimethoxyphenyl)acryloyl]phenyl}acetamide (9h). Yield 52%; yellow powder; mp 135–137 °C; IR (cm^{-1}): 3426 (NH), 3067 (CH aromatic), 2928 (CH aliphatic), 1657 (broad, $2C=O$); 1H NMR (400 MHz, DMSO- d_6) δ 3.70 (s, 3H, OCH_3), 3.82 (s, 3H, OCH_3), 3.86 (s, 3H, OCH_3), 3.96 (t, $J = 7.2$ Hz, 2H, CH_2Cl), 4.23 (s, 2H, CH_2), 4.34 (t, $J = 7.2$ Hz, 2H, OCH_2), 6.82–7.12 (m, 7H, *p*-methoxyphenyl H-3, H-5, *p*-chloroethoxyphenyl H-3, H-5, dimethoxyphenyl H-2, H-5, H-6), 7.38 (d, $J = 15.2$ Hz, 1H, $COCH=CH$), 7.67–7.86 (m, 5H, $COCH=CH$, *p*-methoxyphenyl H-2, H-6, *p*-chloroethoxyphenyl H-2, H-6), 8.18–8.29 (m, 5H, phenyl H-2, H-6, phenyl H-3, H-5, pyrimidin H-5), 10.89 (s, 1H, NH, D_2O exchangeable); ^{13}C NMR (100 MHz, DMSO- d_6) δ 42.2 (CH_2), 43.4 (CH_2Cl), 55.8

(OCH₃), 56.1 (OCH₃), 56.2 (OCH₃), 75.1 (OCH₂), 109.0 (pyrimidine C-5), 111.5 (dimethoxyphenyl C-2), 111.9 (dimethoxyphenyl C-5), 114.5 (*p*-methoxyphenyl C-3, C-5), 115.1 (*p*-chloroethoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 119.8 (COCH=CH), 124.4 (dimethoxyphenyl C-6), 127.3 (dimethoxyphenyl C-1), 127.4 (*p*-chloroethoxyphenyl C-1), 128.0 (*p*-chloroethoxyphenyl C-2, C-6), 128.7 (*p*-methoxyphenyl C-1), 129.6 (*p*-methoxyphenyl C-2, C-6), 130.3 (phenyl C-3, C-5), 131.3 (phenyl C-4), 143.9 (phenyl C-1), 144.4 (COCH=CH), 149.4 (dimethoxyphenyl C-4), 151.6 (dimethoxyphenyl C-3), 157.2 (*p*-chloroethoxyphenyl C-4), 161.2 (*p*-methoxyphenyl C-4), 162.2 (pyrimidine C-6), 164.3 (pyrimidine C-4), 167.6 (pyrimidine C-2), 170.7 (CONH), 187.6 (CO); Anal. Calcd. for C₃₈H₃₄ClN₃O₆S (695.19): C, 65.56; H, 4.92; N, 6.04. Found: C, 65.74; H, 5.07; N, 5.99.

(ZE)-2-[4-(4-(2-Chloroethoxy)phenyl)-6-(4-methoxyphenyl)pyrimidin-2-ylthio]-N-{4-[3-(3,4,5-trimethoxyphenyl)acryloyl]phenyl}acetamide (9i). Yield 54%; yellow powder; mp 116–118 °C; IR (cm⁻¹): 3417 (NH), 3039 (CH aromatic), 2934 (CH aliphatic), 1658 (broad, 2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 3.71 (s, 3H, OCH₃), 3.72 (s, 3H, OCH₃), 3.82 (t, *J* = 3.6 Hz, 2H, CH₂Cl), 3.88 (s, 6H, 2OCH₃), 4.23 (s, 2H, CH₂), 4.34 (t, *J* = 3.6 Hz, 2H, OCH₂), 7.25 (s, 2H, trimethoxyphenyl H-2, H-6), 7.68–7.72 (m, 3H, *p*-chloroethoxyphenyl H-3, H-5 and COCH=CH), 7.81 (d, *J* = 8.8 Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.90 (d, *J* = 8.8 Hz, 2H, phenyl H-3, H-5), 7.95 (d, *J* = 8.2 Hz, *p*-chloroethoxyphenyl H-2, H-6), 8.20–8.22 (m, 4H, phenyl H-2, H-6 and *p*-methoxyphenyl H-2, H-6), 8.29–8.31 (m, 2H, COCH=CH and pyrimidin H-5), 10.71 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 43.4 (CH₂), 55.4 (CH₂Cl), 55.8 (OCH₃), 56.5 (2OCH₃), 60.6 (OCH₃), 68.6 (OCH₂), 106.5 (trimethoxyphenyl C-2, C-6), 106.9 (pyrimidine C-5), 114.1 (*p*-methoxyphenyl C-3, C-5), 114.9 (*p*-chloroethoxyphenyl C-3, C-5), 118.9 (phenyl C-2, C-6), 119.8 (COCH=CH), 121.5 (trimethoxyphenyl C-1), 129.6 (*p*-chloroethoxyphenyl C-1), 129.7 (*p*-chloroethoxyphenyl C-2, C-6), 130.4 (phenyl C-3, C-5), 130.7 (*p*-methoxyphenyl C-1), 131.0 (*p*-methoxyphenyl C-2, C-6), 131.6 (phenyl C-4), 140.0 (trimethoxyphenyl C-4), 143.7 (phenyl C-1), 144.4 (COCH=CH), 153.5 (trimethoxyphenyl C-3, C-5), 160.6 (*p*-methoxyphenyl C-4), 161.7 (*p*-chloroethoxyphenyl C-4), 164.1 (pyrimidine C-6), 164.0 (pyrimidine C-4), 168.6 (pyrimidine C-2), 172.3 (CONH), 187.9 (CO); Anal. Calcd. for C₃₉H₃₆ClN₃O₇S (725.20): C, 64.50; H, 5.00; N, 5.79. Found: C, 64.38; H, 4.98; N, 5.53.

(ZE)-2-[4-(4-Chlorophenyl)-6-*p*-tolylpyrimidin-2-ylthio]-N-{4-[3-(4-methoxyphenyl)acryloyl]phenyl}acetamide (9j). Yield 59%; yellow powder; mp 242–244 °C; IR (cm⁻¹): 3256 (NH), 3038 (CH aromatic), 2917 (CH aliphatic), 1663 (broad, 2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 2.36 (s, 3H, CH₃), 3.82 (s, 3H, OCH₃), 4.24 (s, 2H, CH₂), 7.02 (d, *J* = 8.8 Hz, 2H, methoxyphenyl H-3, H-5), 7.27 (d, *J* = 8.0 Hz, 2H, *p*-tolyl H-3, H-5), 7.52 (d, *J* = 8.8 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.69 (d, *J* = 11.6 Hz, 1H, COCH=CH), 7.82 (d, *J* = 11.6 Hz, 1H, COCH=CH), 7.83–7.85 (m, 4H, *p*-tolyl H-2, H-6, *p*-methoxyphenyl H-2, H-6), 8.16 (d, *J* = 8.8 Hz, 2H, phenyl H-2, H-6), 8.22 (d, *J* = 8.8 Hz, 2H, phenyl H-3, H-5), 8.30 (s, 1H, pyrimidine H-5), 8.34 (d, *J* = 8.8 Hz, 2H, *p*-chlorophenyl H-2, H-6), 10.84 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 21.4 (CH₃), 36.4 (CH₂), 55.8 (OCH₃), 108.3 (pyrimidine C-5), 114.8 (*p*-methoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 119.8 (COCH=CH), 127.8 (*p*-tolyl C-2, C-6), 129.3 (*p*-chlorophenyl C-2, C-6), 129.6 (*p*-chlorophenyl C-3, C-5), 129.9 (*p*-tolyl C-3, C-5), 130.3 (*p*-methoxyphenyl C-2, C-6), 131.1 (phenyl C-3, C-5), 133.0 (*p*-methoxyphenyl C-1), 133.3 (*p*-tolyl C-4), 135.1 (*p*-tolyl C-1), 136.6 (phenyl C-4), 142.0 (*p*-chlorophenyl C-1), 143.8 (phenyl C-1), 143.8 (*p*-chlorophenyl C-4), 148.0

(COCH=CH), 161.7 (*p*-methoxyphenyl C-4), 163.4 (pyrimidine C-6), 164.9 (pyrimidine C-4), 167.6 (pyrimidine C-2), 171.1 (CONH), 187.8 (CO); EIMS (*m/z*): 607.20 (*M* + 2, 1.54%), 606.15 (*M* + 1, 1.28%), 605.15 (*M*⁺, 2.65%), 57.10 (100%); Anal. Calcd. for C₃₅H₂₈ClN₃O₃S (605.15): C, 69.35; H, 4.66; N, 6.93. Found: C, 69.41; H, 4.87; N, 7.13.

(ZE)-2-[4-(4-Chlorophenyl)-6-*p*-tolylpyrimidin-2-ylthio]-N-{4-[3-(3,4-dimethoxyphenyl)acryloyl]phenyl}acetamide (9k). Yield 57%; yellow powder; mp 144–146 °C; IR (cm⁻¹): 3273 (NH), 3039 (CH aromatic), 2924 (CH aliphatic), 1665 (broad, 2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 2.35 (s, 3H, CH₃), 3.85 (s, 3H, OCH₃), 3.86 (s, 3H, OCH₃), 4.24 (s, 2H, CH₂), 7.01 (d, *J* = 8.4 Hz, 1H, dimethoxyphenyl H-5), 7.27 (d, *J* = 8.0 Hz, 2H, *p*-tolyl H-3, H-5), 7.37 (d, *J* = 8.4 Hz, 1H, dimethoxyphenyl H-6), 7.50 (d, *J* = 8.8 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.53 (s, 1H, dimethoxyphenyl H-2), 7.69 (d, *J* = 11.6 Hz, 1H, COCH=CH), 7.81 (d, *J* = 11.6 Hz, 1H, COCH=CH), 7.85 (d, *J* = 8.0 Hz, 2H, *p*-tolyl H-2, H-6), 8.18 (d, *J* = 8.0 Hz, 2H, phenyl H-2, H-6), 8.22 (d, *J* = 8.0 Hz, 2H, phenyl H-3, H-5), 8.28 (s, 1H, pyrimidine H-5), 8.34 (d, *J* = 8.8 Hz, 2H, *p*-chlorophenyl H-2, H-6), 10.91 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 21.4 (CH₃), 36.2 (CH₂), 56.1 (OCH₃), 56.8 (OCH₃), 108.3 (pyrimidine C-5), 111.0 (dimethoxyphenyl C-2), 111.9 (dimethoxyphenyl C-5), 118.8 (phenyl C-2, C-6), 119.6 (dimethoxyphenyl C-6), 119.8 (*p*-tolyl C-2, C-6), 124.3 (COCH=CH), 127.8 (*p*-chlorophenyl C-2, C-6), 128.0 (dimethoxyphenyl C-1), 129.3 (*p*-chlorophenyl C-3, C-5), 129.6 (*p*-tolyl C-3, C-5), 129.9 (phenyl C-3, C-5), 130.3 (*p*-tolyl C-4), 133.0 (*p*-tolyl C-1), 133.3 (*p*-chlorophenyl C-1), 134.0 (*p*-chlorophenyl C-4), 135.1 (phenyl C-4), 136.6 (phenyl C-1), 144.7 (COCH=CH), 149.4 (dimethoxyphenyl C-4), 151.6 (dimethoxyphenyl C-3), 163.4 (pyrimidine C-6), 164.9 (pyrimidine C-4), 167.6 (pyrimidine C-2), 171.1 (CONH), 187.9 (CO); Anal. Calcd. for C₃₆H₃₀ClN₃O₄S (635.16): C, 67.97; H, 4.75; N, 6.61. Found: C, 67.85; H, 4.58; N, 6.42.

(ZE)-2-[4-(4-Chlorophenyl)-6-*p*-tolylpyrimidin-2-ylthio]-N-{4-[3-(3,4,5-trimethoxyphenyl)acryloyl]phenyl}acetamide (9l). Yield 62%; yellow powder; mp 234–236 °C; IR (cm⁻¹): 3280 (NH), 3088 (CH aromatic), 2927 (CH aliphatic), 1663 (broad, 2C=O); ¹H NMR (400 MHz, DMSO-d₆) δ 2.36 (s, 3H, CH₃), 3.71 (s, 3H, OCH₃), 3.86 (s, 6H, 2OCH₃), 4.25 (s, 2H, CH₂), 7.23 (s, 2H, trimethoxyphenyl H-2, H-6), 7.28 (d, *J* = 8.0 Hz, 2H, *p*-tolyl H-3, H-5), 7.52 (d, *J* = 8.4 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.69 (d, *J* = 12.8 Hz, 1H, COCH=CH), 7.87 (d, *J* = 8.0 Hz, 2H, *p*-tolyl H-2, H-6), 7.93 (d, *J* = 12.8 Hz, 1H, COCH=CH), 8.19–8.24 (m, 4H, phenyl H-2, H-3, H-5, H-6), 8.31 (s, 1H, pyrimidine H-5), 8.35 (d, *J* = 8.4 Hz, 2H, *p*-chlorophenyl H-2, H-6), 10.86 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO-d₆) δ 21.4 (CH₃), 36.4 (CH₂), 56.0 (2OCH₃), 60.6 (OCH₃), 106.8 (trimethoxyphenyl C-2, C-6), 108.3 (pyrimidine C-5), 118.8 (phenyl C-2, C-6), 121.5 (COCH=CH), 127.9 (*p*-tolyl C-2, C-6), 129.3 (trimethoxyphenyl C-1), 129.9 (*p*-chlorophenyl C-2, C-6), 130.4 (*p*-chlorophenyl C-3, C-5), 130.4 (*p*-tolyl C-3, C-5), 130.7 (phenyl C-3, C-5), 132.8 (*p*-tolyl C-4), 133.3 (*p*-tolyl C-1), 135.1 (phenyl C-4), 136.6 (*p*-chlorophenyl C-1), 140.0 (*p*-chlorophenyl C-4), 142.0 (trimethoxyphenyl C-4), 144.0 (phenyl C-1), 144.4 (COCH=CH), 153.5 (trimethoxyphenyl C-3, C-5), 163.4 (pyrimidine C-6), 164.9 (pyrimidine C-4), 167.6 (pyrimidine C-2), 171.1 (CONH), 187.8 (CO); Anal. Calcd. for C₃₇H₃₂ClN₃O₅S (665.18): C, 66.71; H, 4.84; N, 6.31. Found: C, 66.57; H, 4.76; N, 6.37.

(ZE)-2-[4-(4-Chlorophenyl)-6-(4-nitrophenyl)pyrimidin-2-ylthio]-N-{4-[3-(4-methoxyphenyl)acryloyl]phenyl}acetamide (9m). Yield 55%; yellow powder; mp 190–192 °C; IR (cm⁻¹): 3403 (NH), 3066 (CH aromatic), 2927 (CH aliphatic), 1658 (broad, 2C=O); ¹H NMR

(400 MHz, DMSO- d_6) δ 3.83 (s, 3H, OCH₃), 4.29 (s, 2H, CH₂), 7.03 (d, J = 8.8 Hz, 2H, *p*-methoxyphenyl H-3, H-5), 7.55 (d, J = 8.8 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.72 (d, J = 11.6 Hz, 1H, COCH=CH), 7.77–7.93 (m, 5H, COCH=CH, *p*-methoxyphenyl H-2, H-6, phenyl H-2, H-6), 8.17 (d, J = 8.8 Hz, 2H, phenyl H-3, H-5), 8.28 (d, J = 8.8 Hz, 2H, *p*-nitrophenyl H-2, H-6), 8.40 (d, J = 8.8 Hz, 2H, *p*-chlorophenyl H-2, H-6), 8.50 (s, 1H, pyrimidine H-5), 8.58 (d, J = 8.8 Hz, 2H, *p*-nitrophenyl H-3, H-5), 10.89 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ 38.8 (CH₂), 55.8 (OCH₃), 109.7 (pyrimidine C-5), 114.8 (*p*-methoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 120.1 (COCH=CH), 123.2 (*p*-nitrophenyl C-3, C-5), 124.3 (*p*-nitrophenyl C-2, C-6), 125.8 (*p*-chlorophenyl C-2, C-6), 127.9 (*p*-methoxyphenyl C-1), 129.4 (*p*-chlorophenyl C-3, C-5), 129.4 (*p*-methoxyphenyl C-2, C-6), 133.5 (phenyl C-3, C-5), 133.8 (*p*-chlorophenyl C-1), 134.4 (*p*-chlorophenyl C-4), 134.5 (phenyl C-4), 141.9 (*p*-nitrophenyl C-1), 144.3 (phenyl C-1), 145.4 (COCH=CH), 149.2 (*p*-nitrophenyl C-4), 161.8 (*p*-methoxyphenyl C-4), 162.4 (pyrimidine C-6), 164.6 (pyrimidine C-4), 167.8 (pyrimidine C-2), 171.5 (CONH), 187.5 (CO); Anal. Calcd. for C₃₄H₂₅ClN₄O₅S (636.12): C, 64.10; H, 3.96; N, 8.79. Found: C, 64.24; H, 4.06; N, 8.47.

(ZE)-2-[4-(4-Chlorophenyl)-6-(4-nitrophenyl)pyrimidin-2-ylthio]-N-{4-[3-(3,4-dimethoxyphenyl)acryloyl]phenyl}acetamide (9n). Yield 53%; yellow powder; mp 147–149 °C; IR (cm⁻¹): 3256 (NH), 3079 (CH aromatic), 2922 (CH aliphatic), 1660 (broad, 2C=O); ¹H NMR (400 MHz, DMSO- d_6) δ 3.82 (s, 3H, OCH₃), 3.87 (s, 3H, OCH₃), 4.29 (s, 2H, CH₂), 7.03 (d, J = 8.4 Hz, 1H, dimethoxyphenyl H-5), 7.39 (d, J = 8.4 Hz, 1H, dimethoxyphenyl H-6), 7.53–7.55 (m, 3H, *p*-chlorophenyl H-3, H-5, dimethoxyphenyl H-2), 7.70 (d, J = 15.6 Hz, 1H, COCH=CH), 7.82–7.87 (m, 3H, *p*-chlorophenyl H-2, H-6, COCH=CH), 8.19 (d, J = 8.8 Hz, 2H phenyl H-2, H-6), 8.27 (d, J = 8.8 Hz, 2H phenyl H-3, H-5), 8.38 (d, J = 8.4 Hz, 2H *p*-nitrophenyl H-2, H-6), 8.49 (s, 1H, pyrimidine H-5), 8.57 (d, J = 8.4 Hz, 2H, *p*-nitrophenyl H-3, H-5), 10.88 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ 36.5 (CH₂), 56.0 (OCH₃), 56.1 (OCH₃), 109.9 (pyrimidine C-5), 111.0 (dimethoxyphenyl C-2), 111.9 (dimethoxyphenyl C-5), 118.8 (phenyl C-2, C-6), 119.8 (dimethoxyphenyl C-6), 124.2 (*p*-nitrophenyl C-3, C-5), 124.3 (COCH=CH), 128.0 (*p*-nitrophenyl C-2, C-6), 129.2 (dimethoxyphenyl C-1), 129.4 (*p*-chlorophenyl C-2, C-6), 129.8 (*p*-chlorophenyl C-3, C-5), 130.3 (phenyl C-3, C-5), 133.1 (*p*-chlorophenyl C-1), 134.7 (*p*-chlorophenyl C-4), 137.0 (phenyl C-4), 142.1 (*p*-nitrophenyl C-1), 143.8 (phenyl C-1), 144.4 (COCH=CH), 149.4 (*p*-nitrophenyl C-4), 151.6 (dimethoxyphenyl C-4), 152.3 (dimethoxyphenyl C-3), 162.7 (pyrimidine C-6), 164.1 (pyrimidine C-4), 167.5 (pyrimidine C-2), 171.6 (CONH), 187.8 (CO); Anal. Calcd. for C₃₅H₂₇ClN₄O₆S (666.13): C, 63.01; H, 4.08; N, 8.40. Found: C, 62.89; H, 4.15; N, 8.37.

(ZE)-2-[4-(4-Chlorophenyl)-6-(4-nitrophenyl)pyrimidin-2-ylthio]-N-{4-[3-(3,4,5-trimethoxyphenyl)acryloyl]phenyl}acetamide (9o). Yield 47%; yellow powder; mp 268–270 °C; IR (cm⁻¹): 3371 (NH), 3059 (CH aromatic), 2935 (CH aliphatic), 1656 (broad, 2C=O); ¹H NMR (400 MHz, DMSO- d_6) δ 3.72 (s, 3H, OCH₃), 3.87 (s, 6H, 2OCH₃), 4.29 (s, 2H, CH₂), 7.24 (s, 2H, trimethoxyphenyl H-2, H-6), 7.55 (d, J = 8.8 Hz, 2H, *p*-chlorophenyl H-3, H-5), 7.70 (d, J = 15.6 Hz, 1H, COCH=CH), 7.87 (d, J = 8.8 Hz, 2H, *p*-chlorophenyl H-2, H-6), 7.92 (d, J = 15.6 Hz, 1H, COCH=CH), 8.21 (d, J = 8.8 Hz, 2H, phenyl H-2, H-6), 8.28 (d, J = 8.8 Hz, 2H, phenyl H-3, H-5), 8.39 (d, J = 8.8 Hz, 2H, *p*-nitrophenyl H-2, H-6), 8.51 (s, 1H, pyrimidine H-5), 8.58 (d, J = 8.8 Hz, 2H, *p*-nitrophenyl H-3, H-5), 10.89 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ 36.5 (CH₂), 56.6 (2OCH₃), 60.6 (OCH₃), 106.9 (trimethoxyphenyl C-2, C-6), 110.0 (pyrimidine C-5), 118.8 (phenyl C-2, C-6), 121.5 (COCH=CH), 124.3

(*p*-nitrophenyl C-3, C-5), 129.3 (*p*-nitrophenyl C-2, C-6), 129.4 (*p*-chlorophenyl C-2, C-6), 129.8 (*p*-chlorophenyl C-3, C-5), 130.5 (trimethoxyphenyl C-1), 130.8 (phenyl C-3, C-5), 132.9 (*p*-chlorophenyl C-1), 134.8 (*p*-chlorophenyl C-4), 137.0 (phenyl C-4), 140.0 (trimethoxyphenyl C-4), 142.1 (phenyl C-1), 143.9 (*p*-nitrophenyl C-1), 144.4 (COCH=CH), 149.5 (*p*-nitrophenyl C-4), 153.5 (trimethoxyphenyl C-3, C-5), 162.8 (pyrimidine C-6), 164.2 (pyrimidine C-4), 167.5 (pyrimidine C-2), 171.6 (CONH), 187.8 (CO); EIMS (m/z): 696.20 (M⁺, 0.11%), 86.15 (100%); Anal. Calcd. for C₃₆H₂₉ClN₄O₇S (696.14): C, 62.02; H, 4.19; N, 8.04. Found: C, 61.98; H, 4.35; N, 7.98.

(ZE)-2-[4-[4-(2-Chloroethoxyphenyl)phenyl]-6-(4-chlorophenyl)-pyrimidin-2-ylthio]-N-{4-[3-(4-methoxyphenyl)acryloyl]phenyl}acetamide (9p). Yield 52%; yellow powder; mp 136–138 °C; IR (cm⁻¹): 3181 (NH), 3043 (CH aromatic), 2927 (CH aliphatic), 1663 (broad, 2C=O); ¹H NMR (400 MHz, DMSO- d_6) δ 3.83 (s, 3H, OCH₃), 3.97 (t, J = 6.9 Hz, 2H, CH₂Cl), 4.25 (s, 2H, CH₂), 4.32 (t, J = 6.9 Hz, 2H, OCH₂), 6.90–7.14 (m, 4H, methoxyphenyl H-3, H-5, *p*-chloroethoxyphenyl H-3, H-5), 7.43–7.69 (m, 10H, COCH=CH, COCH=CH, phenyl H-2, H-6, *p*-methoxyphenyl H-2, H-6, *p*-chloroethoxyphenyl H-2, H-6, *p*-chlorophenyl H-3, H-5), 8.12–8.35 (m, 5H, phenyl H-3, H-5, pyrimidine H-5, *p*-chlorophenyl H-2, H-6), 10.88 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ 36.2 (CH₂), 43.4 (CH₂Cl), 54.6 (OCH₃), 55.8 (OCH₂), 107.8 (pyrimidine C-5), 114.8 (*p*-methoxyphenyl C-3, C-5), 115.3 (*p*-chloroethoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 121.8 (COCH=CH), 127.4 (*p*-chloroethoxyphenyl C-1), 128.5 (*p*-methoxyphenyl C-1), 128.6 (*p*-chlorophenyl C-2, C-6), 129.4 (*p*-chlorophenyl C-3, C-5), 129.6 (*p*-methoxyphenyl C-2, C-6), 129.6 (*p*-chloroethoxyphenyl C-2, C-6), 130.7 (*p*-chlorophenyl C-1), 132.7 (phenyl C-3, C-5), 133.9 (*p*-chlorophenyl C-4), 140.1 (phenyl C-4), 143.0 (phenyl C-1), 144.4 (COCH=CH), 159.4 (*p*-chloroethoxyphenyl C-4), 159.9 (*p*-methoxyphenyl C-4), 162.8 (pyrimidine C-6), 164.3 (pyrimidine C-4), 167.3 (pyrimidine C-2), 171.4 (CONH), 187.8 (CO); Anal. Calcd. for C₃₆H₂₉Cl₂N₃O₄S (669.13): C, 64.48; H, 4.36; N, 6.27. Found: C, 64.36; H, 4.19; N, 6.35.

(ZE)-2-[4-[4-(2-Chloroethoxyphenyl)phenyl]-6-(4-chlorophenyl)-pyrimidin-2-ylthio]-N-{4-[3-(3,4-dimethoxyphenyl)acryloyl]phenyl}acetamide (9q). Yield 49%; yellow powder; mp 210–212 °C; IR (cm⁻¹): 3429 (NH), 3061 (CH aromatic), 2927 (CH aliphatic), 1663 (broad, 2C=O); ¹H NMR (400 MHz, DMSO- d_6) δ 3.72–3.82 (m, 5H, OCH₃ and CH₂Cl), 3.83–3.88 (m, 5H, OCH₃ and OCH₂), 4.34 (s, 2H, CH₂), 6.98–7.15 (m, 4H, dimethoxyphenyl H-5, H-6, *p*-chloroethoxyphenyl H-3, H-5), 7.31–7.40 (m, 2H, dimethoxy H-2 and COCH=CH), 7.52–7.70 (m, 4H, *p*-chlorophenyl H-3, H-5 and *p*-chloroethoxyphenyl H-2, H-6), 7.75–7.88 (m, 4H, phenyl H-2, H-6 and *p*-chlorophenyl H-2, H-6), 7.95 (d, J = 8.8 Hz, 2H, phenyl H-3, H-5), 8.28 (d, J = 12.0 Hz, 1H, COCH=CH), 8.46 (s, 1H, pyrimidine H-5), 10.76 (s, 1H, NH, D₂O exchangeable); ¹³C NMR (100 MHz, DMSO- d_6) δ 38.4 (CH₂), 42.9 (CH₂Cl), 56.1 (OCH₃), 56.6 (OCH₃), 68.6 (OCH₂), 107.3 (pyrimidine C-5), 111.5 (dimethoxyphenyl C-2), 112.7 (dimethoxyphenyl C-5), 114.9 (*p*-chloroethoxyphenyl C-3, C-5), 121.1 (phenyl C-2, C-6), 121.3 (COCH=CH), 122.5 (dimethoxyphenyl C-6), 127.3 (dimethoxyphenyl C-1), 127.4 (*p*-chloroethoxyphenyl C-1), 128.1 (*p*-chloroethoxyphenyl C-2, C-6), 128.9 (*p*-chlorophenyl C-2, C-6), 129.3 (*p*-chlorophenyl C-3, C-5), 131.4 (phenyl C-3, C-5), 133.9 (*p*-chlorophenyl C-1), 134.3 (*p*-chlorophenyl C-4), 135.5 (phenyl C-4), 144.3 (phenyl C-1), 145.1 (COCH=CH), 149.3 (dimethoxyphenyl C-4), 149.7 (dimethoxyphenyl C-3), 151.1 (*p*-chloroethoxyphenyl C-4), 162.5 (pyrimidine C-6), 164.4 (pyrimidine C-4), 168.7 (pyrimidine C-2), 172.7 (CONH), 189.7 (CO); Anal. Calcd.

for $C_{37}H_{31}Cl_2N_3O_5S$ (699.14): C, 63.43; H, 4.46; N, 6.00. Found: C, 63.33; H, 4.27; N, 6.11.

(ZE)-2-[4-[4-(2-Chloroethoxyphenyl)phenyl]-6-(4-chlorophenyl)-pyrimidin-2-ylthio]-N-[4-[3-(3,4,5-trimethoxyphenyl)acryloyl]phenyl]acetamide (9r). Yield 53%; yellow powder; mp 221–223 °C; IR (cm^{-1}): 3421 (NH), 3061 (CH aromatic), 2931 (CH aliphatic), 1665 (broad, $2C=O$); 1H NMR (400 MHz, $DMSO-d_6$) δ 3.70 (s, 3H, OCH_3), 3.85 (s, 6H, $2OCH_3$), 3.96 (t, $J = 7.2$ Hz, 2H, CH_2Cl), 4.24 (s, 2H, CH_2), 4.45 (t, $J = 7.2$ Hz, 2H, OCH_2), 7.03–7.20 (m, 4H, trimethoxyphenyl H-2, H-6, chloroethoxyphenyl H-3, H-5), 7.29 (d, $J = 12.0$ Hz, 1H, $COCH=CH$), 7.51–7.60 (m, 4H, *p*-chlorophenyl H-3, H-5, chloroethoxyphenyl H-2, H-6), 7.87–7.96 (m, 3H, phenyl H-2, H-6, $COCH=CH$), 8.18–8.32 (m, 5H, phenyl H-3, H-5, *p*-chlorophenyl H-2, H-6, pyrimidine H-5), 10.91 (s, 1H, NH, D_2O exchangeable); ^{13}C NMR (100 MHz, $DMSO-d_6$) δ 36.8 (CH_2), 43.9 (CH_2Cl), 55.5 ($2OCH_3$), 57.8 (OCH_2), 60.8 (OCH_3), 106.7 (trimethoxyphenyl C-2, C-6), 109.4 (pyrimidine C-5), 114.9 (*p*-chloroethoxyphenyl C-3, C-5), 118.8 (phenyl C-2, C-6), 121.5 ($COCH=CH$), 126.4 (trimethoxyphenyl C-1), 127.4 (*p*-chloroethoxyphenyl C-1), 128.1 (*p*-chloroethoxyphenyl C-2, C-6), 129.5 (*p*-chlorophenyl C-2, C-6), 129.8 (*p*-chlorophenyl C-3, C-5), 132.7 (phenyl C-3, C-5), 135.4 (*p*-chlorophenyl C-1), 136.8 (*p*-chlorophenyl C-4), 140.3 (phenyl C-4), 141.7 (trimethoxyphenyl C-4), 143.0 (phenyl C-1), 144.4 ($COCH=CH$), 153.5 (trimethoxyphenyl C-3, C-5), 159.4 (*p*-chloroethoxyphenyl C-4), 162.2 (pyrimidine C-6), 164.1 (pyrimidine C-4), 167.7 (pyrimidine C-2), 171.7 (CONH), 187.7 (CO); EIMS (m/z): 728.10 (M-1, 0.28%), 58.10 (100%); Anal. Calcd. for $C_{38}H_{33}Cl_2N_3O_6S$ (729.15): C, 62.47; H, 4.55; N, 5.75. Found: C, 62.53; H, 4.76; N, 5.58.

Biological evaluations

Cytotoxic assay

To investigate cytotoxic activity of the final target compounds **9a–r**, MTT assay was performed. Three different cell lines were used, leukaemia (K-562), breast (MCF-7) and colon (HT-29) cell lines. Cisplatin and erlotinib were the reference drugs used in this study. Half maximal concentration at which 50% of cells were viable was calculated as IC_{50} in μM , according to cytotoxic assay reported protocol⁴⁷.

STAT3/STAT5a assays

Both K-562 and MCF-7 cell lines were seeded overnight in plates, then 10 μM of test compounds (**9a** and **9r** for MCF-7 cells; **9d**, **9f**, and **9n** for K-562 cells) or reference drug pacritinib was added for 24 h. A nuclear extract kit was used to extract nuclear fractions from treated cells using the manufacture's procedure. STAT3 and STAT5a activations were analysed using the collected nuclear extracts (20 μg) through TransAM STAT3 and STAT5a activation assay guided by the manufacture's protocol. The obtained results were expressed in the form of mean \pm SD. Each experiment was done in triplicate.

Biological properties

The target compounds **9a–r** were drawn using ChemDraw Ultra 10.0. Biological properties and drug likeness were predicted using online computational tool Molinspiration⁴⁸.

Predicted pharmacokinetic and toxicity properties

Pharmacokinetic properties (absorption, distribution, metabolism, and excretion) through determination of human intestinal absorption (HIA), *in vitro* caco-2 cell permeability, *in vitro* Madin-Darby Canine Kidney (MDCK) cell permeability, plasma protein binding (PPB), blood–brain binding (BBB), skin permeability, p-glycoprotein (Pgp), and cytochrome p450 isoforms inhibition data, in addition to toxicity (Ames test, rodent carcinogenicity assay and hERG-inhibition) were evaluated through preADMET online server⁴⁹.

Statistical analysis

Data obtained were expressed as means \pm standard deviations (SDs). The results were considered significant when $^*p < 0.05$ or $^{**}p < 0.005$ using Student's *t*-test was compared to reference drugs. The obtained values were representative of triplicate independent experiments.

Results and discussion

Chemistry

The target 2-TP/chalcone hybrids **9a–r** were prepared from two synthesised starting materials **4a–f** and **8a–c**, as depicted in Schemes 1–3.

Heating under reflux condition chalcone derivatives **3a–f** (synthesised from condensation of *p*-methoxy/chlorobenzaldehyde **1a&b** with *p*-methyl/nitro/or ethoxychloroacetophenone **2a–c**) and thiourea in presence of KOH afforded 2-TP derivatives **4a–f**. The method was reported for compounds **4b** and **4d**^{39,50} (Scheme 1).

The other starting materials, chloroacetyl chalcone derivatives **8a–c** were obtained by stirring *p*-aminochalcone derivatives **7a–c** with chloroacetyl chloride, K_2CO_3 in chloroform at room temperature²⁴ (Scheme 2).

S-Alkylation of 2-TPs **4a–f** with acetylated chalcones **8a–c** was achieved in acetonitrile using TEA as a base catalysis to obtain the target compounds **9a–r** in 47–82% yield.

1H NMR and ^{13}C NMR spectroscopic tools were used to confirm formation of the target derivatives **9a–r**. Thus, 1H NMR spectra of compounds **9a–r** displayed a singlet signal at δ 3.82–4.84 ppm attributed to (SCH_2CO) protons. Additionally, protons of chalcone fragment appeared as two doublet signals at δ 7.29–7.72 ppm and 7.69–8.31 ppm with coupling constant $J = 11.6$ – 15.6 Hz. Furthermore, amide NH proton appeared as a singlet signal at δ 10.71–10.91 ppm.


^{13}C NMR spectra of compounds **9a–r** showed appearance of a peak at δ 36.21–43.44 ppm characterised to SCH_2 carbon. Moreover, two carbonyl carbons at δ 170.71–173.07 ppm and 187.58–190.01 ppm related to (NHCO) and ($C=O$), respectively, were also appeared (Scheme 3).

Biological activity


Cytotoxic activity

All target compounds **9a–r** were screened against three different cancer cell lines, leukaemia (K-562), breast (MCF-7), and colon (HT-29). MTT assay was used. Both cisplatin and erlotinib were used as the reference drugs. Cytotoxicity results are recorded in Table 1.

Regarding cytotoxic activity of the test compounds against leukaemia (K-562) cell line, compounds **9d**, **9f**, **9n**, and **9p** were the most potent compounds with IC_{50} ranged from 0.77 to 1.74 μM if compared to cisplatin, the reference drug ($IC_{50} = 2.31 \mu M$). Their



Scheme 1. Synthesis of 2-thiopyrimidine derivatives 4a–f.



Scheme 2. Synthesis of chloroacetyl amino chalcone derivatives 8a–c.

common feature was presence of one or more *para* substituted phenyl ring(s) with electron withdrawing group (NO₂, Cl) at pyrimidine core.

Compounds **9b**, **9e**, **9g–j**, **9m**, and **9q** exhibited potent inhibitory activity with IC₅₀ values ranged from 3.17 to 9.71 μM, if compared to the second reference erlotinib (IC₅₀: 9.85 μM). *P*-Methoxyacyloyl derivative **9k**, with IC₅₀ value = 9.95 μM, was nearly equal in potency to erlotinib. Compounds **9a**, **9c**, **9o**, and **9r** showed moderate inhibitory activity (IC₅₀=10.67–18.40 μM). The lowest inhibitory activity was observed in compound **9l** (IC₅₀=42.60 μM), bearing *p*-chlorophenyl and *p*-tolyl rings at pyrimidine scaffold, beside, trimethoxyphenyl chalcone hybrid.

Concerning MCF-7 cell line, the most active derivative was **9r** (IC₅₀=1.37 μM) compared to the reference drug cisplatin (IC₅₀=6.62 μM). It is characterised by presence of *p*-chlorophenyl ring and *p*-chloroethoxyphenyl ring at pyrimidine core together with trimethoxy chalcone part.

Other compounds exerted excellent activity were **9a**, **9c**, **9f**, **9j**, **9m**, and **9o** (IC₅₀=3.56–6.26 μM). Additionally, compound **9q** was nearly equipotent to the reference drug cisplatin (IC₅₀=6.81 μM). Derivatives **9g** and **9h** with IC₅₀=10.40 and 7.70 μM, respectively, were more potent than erlotinib (IC₅₀=10.64 μM).

Moderate activity was observed in compounds **9d**, **9e**, **9i**, **9l**, **9n**, and **9p** (IC₅₀=11.47–18.74 μM).


Compounds **9b** and **9k** showed weak inhibitory activity with IC₅₀ values equal to 22.45 and 28.65 μM, respectively. Both of them have dimethoxyphenyl ring on chalcone part, and *p*-tolyl ring at pyrimidine core.

By inspecting cytotoxicity results of HT-29 cell line, compounds **9a**, **9l**, and **9n** showed IC₅₀ (2.10–2.37 μM) near in potency to the reference drug cisplatin (IC₅₀=1.12 μM). Compounds **9c**, **9e**, **9j**, **9k**, **9m**, **9o**, **9q**, and **9r** showed significant activity with IC₅₀ values between 3.62 and 8.70 μM, compared to erlotinib (IC₅₀=9.20 μM). While, rest of the compounds exhibited weak inhibitory activity (IC₅₀=9.41–25.92 μM). Results showed that no effect was observed regarding substituents on the two hybrid structures pyrimidine and chalcone.

Finally, dual cytotoxic activity was observed for compound **9f** (against K-562 and MCF-7 cell lines), and for compound **9a** (on MCF-7 and HT-29 cell lines) and **9n** (against K-562 and HT-29 cell lines).

Cytotoxicity against normal cell line (WI38)

To know cytotoxicity of the most active compounds, they were tested against normal human fibroblast cell line (WI38) and IC₅₀ values are represented as in Figure 2. Cisplatin was used as a reference drug. All the test compounds showed higher IC₅₀ values (29.19–40.13 μM) than the reference drug (18.86 μM) except



Scheme 3. Synthesis of the target compounds **9a-r**.

compound **9a** which exerted cytotoxic activity (IC₅₀=17.09 μM) slightly less than cisplatin.

STAT3 and STAT5a inhibitory activity determination

The most active compounds in cytotoxic assay against leukaemia cell line K-562 and human breast adenocarcinoma cells MCF-7 were further tested as inhibitors for STAT3 and STAT5a enzymes. Pacritinib, an inhibitor for both STAT3 and STAT5a⁴⁹ was used in this study as a reference drug.

The results are listed in Table 2. They indicated that the test compounds showed inhibitory activity against both STAT3 and STAT5a. Compounds **9d**, **9n**, and **9r** were the most active against STAT3. Additionally, compound **9n** was the most effective as STAT5a inhibitor. Compounds **9a**, **9f**, and **9r** had also strong inhibitory activity against STAT5a. Dual inhibitory activity against


STAT3 and STAT5a was observed mainly in compound **9n**. For this compound, both phenyl rings on pyrimidine core were *para*-substituted with electron withdrawing groups (NO₂ and Cl), beside presence of disubstituted methoxyphenyl ring at chalcone hybrid.

Biological properties

Molinspiration was used to predict bioactivity scores for all the target compounds **9a-r**. The obtained results are recorded in Table 3. It was found that most of the prepared compounds had bioactivity values in the range -0.5 to 0.00. This revealed that the designed pyrimidine/chalcone derivatives might be involved in moderate interactions with G-protein-coupled receptors (GPCRs) and protease inhibitors. However, the bioactivity prediction was not in the standard range against other receptors such as ion channel modulator, kinases and nuclear receptor ligand.

Table 1. Cytotoxicity results of pyrimidine/chalcone hybrids **9a–r** against three different cancer cell lines.

						(IC ₅₀ μM)±SD		
Compound	R	R ¹	R ²	R ³	K-562	MCF-7	HT-29	
9a	OCH ₃	CH ₃	H	H	18.40 ± 0.76	3.56 ± 0.14	2.20 ± 0.04	
9b	OCH ₃	CH ₃	CH ₃	H	3.62 ± 0.08	22.45 ± 1.57	16.36 ± 0.76	
9c	OCH ₃	CH ₃	OCH ₃	OCH ₃	11.42 ± 0.04	4.25 ± 0.13	8.70 ± 0.28	
9d	OCH ₃	NO ₂	H	H	0.77 ± 0.03	14.16 ± 0.74	25.92 ± 1.67	
9e	OCH ₃	NO ₂	OCH ₃	H	7.05 ± 0.28	18.74 ± 0.92	7.31 ± 0.36	
9f	OCH ₃	NO ₂	OCH ₃	OCH ₃	1.37 ± 0.03	5.77 ± 0.22	9.41 ± 0.43	
9g	OCH ₃	OCH ₂ CH ₂ Cl	H	H	3.17 ± 0.11	10.40 ± 0.64	10.55 ± 0.47	
9h	OCH ₃	OCH ₂ CH ₂ Cl	OCH ₃	H	7.07 ± 0.31	7.70 ± 0.32	18.77 ± 0.88	
9i	OCH ₃	OCH ₂ CH ₂ Cl	OCH ₃	OCH ₃	9.71 ± 0.41	11.47 ± 0.81	11.47 ± 0.23	
9j	Cl	CH ₃	H	H	4.26 ± 0.06	6.26 ± 0.24	6.26 ± 0.34	
9k	Cl	CH ₃	OCH ₃	H	9.95 ± 0.29	28.65 ± 1.39	5.61 ± 0.18	
9l	Cl	CH ₃	OCH ₃	OCH ₃	42.60 ± 1.99	13.46 ± 0.62	2.37 ± 0.07	
9m	Cl	NO ₂	H	H	3.86 ± 0.14	3.90 ± 0.09	7.90 ± 0.22	
9n	Cl	NO ₂	OCH ₃	H	1.05 ± 0.02	17.36 ± 0.75	2.10 ± 0.06	
9o	Cl	NO ₂	OCH ₃	OCH ₃	12.35 ± 0.72	3.62 ± 0.084	3.62 ± 0.08	
9p	Cl	OCH ₂ CH ₂ Cl	H	H	1.74 ± 0.04	11.64 ± 0.49	11.64 ± 0.63	
9q	Cl	OCH ₂ CH ₂ Cl	OCH ₃	H	5.77 ± 0.16	6.81 ± 0.25	6.06 ± 0.29	
9r	Cl	OCH ₂ CH ₂ Cl	OCH ₃	OCH ₃	10.67 ± 0.77	1.37 ± 0.07	4.74 ± 0.27	
Cisplatin					2.31 ± 0.09	6.62 ± 0.29	1.12 ± 0.06	
Erlotinib					9.85 ± 0.51	10.64 ± 0.58	9.20 ± 0.41	

**Figure 2.** Cytotoxicity (IC₅₀) of the most active derivatives and cisplatin against WI38 cell line.

Drug likeness is a complex balance between various molecular properties like, molecule size, hydrogen bonding characters, electronic distribution and hydrophobicity⁵¹. The results in Table 3 showed that all the final target compounds had positive predictable score values which stranded for good drug likeness behaviour, especially compound **9r** as represented in Figure 3.

Predicted pharmacokinetic and toxicity properties

Prediction of the major pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion, in addition to toxicological properties, such as mutagenicity, carcinogenicity, and

cardiac toxicity was estimated using Pharmacokinetics/PreADMET Toxicity Predictor⁵² (Table 4).

Absorption refers to the process by which the drug can go to the systemic circulation through the organs of the body. Several routes for absorption such as oral absorption (human intestinal absorption, HIA), skin permeability (SP, logKp), and permeability through certain cells such as Caco2 (derived from human colon adenocarcinoma cells) and MDCK cells were measured.

By inspecting results recorded in Table 4, it was found that compounds **9a–r** showed good intestinal absorption all above 97.25% (permissible limit: 70–100%abs). Skin permeability was found to be slightly less than acceptable range (–2.5 logKp).

Moreover, moderate permeability through *in vitro* Caco2 cells ranged from 54.34 to 28.65 nm/sc were observed. While, low values were detected for *in vitro* MDCK cells.

The second property is the distribution, through which the transformation of the molecules from one tissue or organ to another can be predicted. Blood–brain barrier (BBB) and PPB were two distribution parameters used in this study. BBB permits the diffusion of hydrophobic and small molecules to the brain. It is an important predictor for central nervous system (CNS) drug discovery. Moreover, the measured of percentage of a molecule bound to plasma protein (%PPB) was also helpful in prediction of distribution for the novel target compounds.

Results showed that all the test compounds displayed strong PPB value (90.94–99.63%) indicating prolonged half-lives and limited brain penetration. Consequently, BBB (unbound brain-to-plasma ratio) was low in most compounds except in nitrophenyl containing derivatives **9d–9f** and **9m–9o** (0.37–0.57) which was medium and around the acceptable range to be CNS active compounds (>0.4).

Metabolism, the biotransformation or chemical modification of exogenous compounds to increase their water solubility by increasing their hydrophobicity facilitating their excretion can be predicted either in phase I or phase II. Cytochrome P450 isoforms, calculate the ability of the test compounds to be inhibitor to drug metabolising enzymes such as CYP2C19, CYP2C9, CYP2D6, CYP3A4, and CYP1A2. Moreover, glycoprotein (P-gp) inhibition measured to predict excretion property of the target compounds.

The test compounds showed good inhibitory behaviour for CYP2C9 and CYP3A4 and did not show inhibition behaviour for CYP2C19 and CYP3A4. All compounds had inhibitory effect on P-gp.

Table 2. STAT3 and STAT5a inhibitory activity of compounds **9a**, **9d**, **9f**, **9n**, **9r** and reference drug pacritinib.

Compound/no.	Inhibition IC ₅₀ (μM)	
	STAT3	STAT5a
9a /MCF7	242.53 ± 9.24	83.78 ± 3.28
9d /K562	160.01 ± 4.59	116.31 ± 4.13
9f /K562	244.74 ± 11.07	77.65 ± 2.91
9n /K562	113.31 ± 3.22	50.75 ± 1.26
9r /MCF7	148.69 ± 3.81	63.24 ± 1.57
Pacritinib/MCF7	79.47 ± 2.17	54.35 ± 1.09
Pacritinib/K562	65.49 ± 2.55	69.81 ± 1.82

Table 3. Biological properties, prediction, and drug likeness of the target compounds.

Compound	GPCR ligand	Ion channel modulator	Kinase inhibitor	Nuclear receptor ligand	Protease inhibitor	Drug likeness score
9a	−0.43	−1.03	−0.58	−0.69	−0.43	0.49
9b	−0.56	−1.27	−0.78	−0.90	−0.51	0.54
9c	−0.73	−1.55	−1.01	−1.17	−0.62	0.96
9d	−0.61	−1.25	−0.83	−0.92	−0.53	0.07
9e	−0.78	−1.53	−1.07	−1.17	−0.65	0.11
9f	−0.99	−1.86	−1.35	−1.50	−0.80	0.49
9g	−0.69	−1.44	−0.81	−1.01	−0.56	0.83
9h	−0.88	−1.75	−1.08	−1.29	−0.70	0.79
9i	−1.11	−2.09	−1.39	−1.64	−0.87	1.18
9j	−0.39	−0.94	−0.52	−0.63	−0.44	0.82
9k	−0.50	−1.16	−0.68	−0.81	−0.50	0.80
9l	−0.64	−1.41	−0.89	−1.06	−0.58	1.07
9m	−0.55	−1.13	−0.75	−0.83	−0.52	0.43
9n	−0.69	−1.39	−0.95	−1.06	−0.62	0.40
9o	−0.88	−1.69	−1.21	−1.36	−0.74	0.63
9p	−0.61	−1.31	−0.71	−0.91	−0.54	1.14
9q	−0.79	−1.60	−0.96	−1.17	−0.66	1.05
9r	−1.00	−1.92	−1.24	−1.49	−0.81	1.40

Prediction of toxicological behaviour of the test compounds was obtained by measuring AMES test (to predict mutagenicity of the compounds), carcino-Mouse/Rate (to test carcinogenicity of the compounds), and hERG-inhibition (to check cardiac toxicity of the target synthesised molecules) (Table 5). Half of test compounds showed non-mutagenic behaviour in AMES test. All compounds had negative carcinogenic effect in mouse and rats, in addition to medium risk as cardiotoxic agents. From the predicted ADMET properties of the novel synthesised compounds, it was justified that they may have good characters as lead compounds.

Structure–activity relationship of target compounds

Structure–activity relationship (SAR) study for the target compounds **9a–r** focussed on two important scaffolds, pyrimidine and chalcone. There was a relationship between presence of small electron donating group such as $-\text{CH}_3$, (D_s), large electron donating group such as $-\text{OCH}_2\text{CH}_2\text{Cl}$, (D_l) or electron withdrawing group, $-\text{NO}_2$, (W) in *para* position of phenyl ring at pyrimidine C-4 and electron donating group, $-\text{OCH}_3$, (D) or electron withdrawing group, $-\text{Cl}$, (W) in *para* position of phenyl ring at pyrimidine C-6 with that of (mono-, di-, or tri-)methoxyphenyl ring of chalcone part, and between cytotoxic activities on the three different tested cell lines K-562, MCF-7, and HT-29, as represented in Figure 4.

In compounds **9a–c**, pyrimidine core carried *p*-tolyl group and *p*-methoxyphenyl group at C-4 and C-6, respectively. Cytotoxic activity against K-562 cell line was maximised in compound **9b** bearing dimethoxyphenyl chalcone moiety then decreased in **9c** and **9a** (trimethoxyphenyl and methoxyphenyl chalcones, respectively).

The order of reactivity was altered when evaluated against MCF-7 or HT-29 cell lines, where **9a**>**9c**>**9b**.

For compounds **9d–f**, replacement of *p*-tolyl group at pyrimidine C-4 with *p*-nitrophenyl group and keeping *p*-methoxyphenyl group at pyrimidine C-6 constant, led to variation in cytotoxic activity. Thus, compound **9d** (with *p*-methoxyphenyl chalcone part) was the most potent against K-562 cell line, than **9f** (trimethoxyphenyl chalcone analogue) and finally **9e** (dimethoxyphenyl chalcone analogue). While against MCF-7, the order was **9f**>**9d**>**9e**. For HT-29, **9e** was the most potent than **9f** and at last **9d**.

Regarding compounds **9g–i**, they characterised by bearing electron donating groups at *para* position of two phenyl rings at pyrimidine C-4 and C-6; however, presence of large sized electron

donating group such as $-OCH_2CH_2Cl$ at phenyl ring of pyrimidine C-4 led to increase its lipophilic character.

The order of cytotoxic activity against K-562 was found to be **9g** (methoxyphenyl chalcone) > **9h** (dimethoxyphenyl chalcone) > **9i** (trimethoxyphenyl chalcone), and for MCF-7 cell line was, **9h** > **9g** > **9i**. While converted to be **9i** > **9g** > **9h** in case of HT-29 cell line.

In **9j-l** derivatives, electron withdrawing group ($-Cl$) was introduced to *para* position of phenyl ring at pyrimidine C-6, while pyrimidine C-4 carried small sized electron donating group ($-CH_3$) at *para* position of its phenyl ring.

The most active compound was **9j** (methoxyphenyl chalcone) in both K-562 and MCF-7 cell lines, while **9l** (trimethoxyphenyl chalcone) was the most potent against HT-29 cell line.

Compounds **9m-o**, *p*-tolyl ring were replaced with *p*-nitrophenyl ring at pyrimidine C-4, while *p*-chlorophenyl ring at pyrimidine C-6 was kept constant.

The most potent derivatives against K-562 were dimethoxyphenyl chalcone **9n**, than methoxyphenyl chalcone derivative **9m**. While, trimethoxyphenyl chalcone derivative **9o** and methoxyphenyl chalcone analogue **9m** showed nearly equal potency

against MCF-7. For HT-29, **9n** was the most potent than **9o** and finally **9m**.

In compounds **9p-r**, incorporation of *p*-chloroethoxyphenyl group at pyrimidine C-4, while keeping *p*-chlorophenyl group at pyrimidine C-6 constant, resulted in changing order of cytotoxic activity against K-562 to be **9p** (methoxyphenyl chalcone) > **9q** (dimethoxyphenyl chalcone), and still the least potent compound was **9r** (trimethoxyphenyl chalcone). However, for MCF-7 and HT-29, it was observed that **9r** was the most potent than **9q** and finally **9p**.

Conclusions

A novel series of 2-TP/chalcone hybrids **9a-r** was designed to be as anticancer agents. They were synthesised and identified using different spectroscopic techniques. Their cytotoxic activities against three different cancerous cell lines, K-562, MCF-7, and HT-29 were evaluated. The synthesised compounds showed strong to moderate cytotoxic activities especially against K-562 and MCF-7 cell lines. The highest cytotoxic activity against K-562 cell line was observed in compounds **9d**, **9f**, **9n**, and **9p** with IC_{50} values in the range of 0.77–1.74 μM , compared to the reference drug, cisplatin (IC_{50} = 2.31 μM). For cytotoxic activity against MCF-7 cell line, compounds **9a**, **9c**, **9f**, **9j**, **9m**, **9o**, and **9r** exhibited the highest




Figure 3. Drug likeness score value (1.40) for compound **9r**.

Table 5. Toxicity assessment of the target synthesised compounds **9a-r**.

Compound	AMES	Carcino-Mouse	Carcino-Rat	hERG-inhibition
9a	Mutagen	Negative	Negative	Medium
9b	Non-mutagen	Negative	Negative	Medium
9c	Non-mutagen	Negative	Negative	Medium
9d	Mutagen	Negative	Negative	Medium
9e	Mutagen	Negative	Negative	Medium
9f	Mutagen	Negative	Negative	Medium
9g	Non-mutagen	Negative	Negative	Medium
9h	Non-mutagen	Negative	Negative	Medium
9i	Non-mutagen	Negative	Negative	Medium
9j	Mutagen	Negative	Negative	Medium
9k	Mutagen	Negative	Negative	Medium
9l	Non-mutagen	Negative	Negative	Medium
9m	Mutagen	Negative	Negative	Medium
9n	Mutagen	Negative	Negative	Medium
9o	Mutagen	Negative	Negative	Medium
9p	Non-mutagen	Negative	Negative	Medium
9q	Non-mutagen	Negative	Negative	Medium
9r	Non-mutagen	Negative	Negative	Medium

Table 4. Pharmacokinetic properties assessment of the target synthesised compounds **9a-r**.

Compound	Absorption				Distribution		Metabolism (CYP) and excretion				
	HIA (%)	SP LogP (cm/h)	Caco2 (nm/sc)	MDCK (nm/sc)	BBB (c.brain/c.blood)	PPB %	2C19	2C9	2D6	3A4	Pgp Inh.
9a	97.50	−1.72	54.34	0.05	0.03	98.31	No	Yes	No	Yes	Inh.
9b	97.36	−1.73	54.31	0.06	0.03	99.63	No	Yes	No	Yes	Inh.
9c	97.25	−1.74	54.26	0.06	0.03	97.83	No	Yes	No	Yes	Inh.
9d	98.78	−2.26	28.65	0.04	0.49	92.53	No	Yes	No	Yes	Inh.
9e	99.22	−2.25	29.60	0.04	0.45	96.23	No	Yes	No	Yes	Inh.
9f	99.39	−2.22	30.34	0.04	0.38	96.95	No	Yes	No	Yes	Inh.
9g	97.69	−2.09	37.98	0.05	0.02	92.10	No	Yes	No	Yes	Inh.
9h	97.54	−2.03	38.68	0.05	0.02	95.16	No	Yes	No	Yes	Inh.
9i	97.42	−1.96	39.36	0.05	0.02	95.17	No	Yes	No	Yes	Inh.
9j	97.95	−1.74	51.82	0.06	0.08	90.94	No	Yes	No	Yes	Inh.
9k	97.83	−1.74	52.19	0.07	0.05	94.17	No	Yes	No	Yes	Inh.
9l	97.69	−1.73	52.52	0.07	0.04	94.05	No	Yes	No	Yes	Inh.
9m	97.49	−2.28	33.88	0.04	0.37	93.03	No	Yes	No	Yes	Inh.
9n	97.96	−2.28	35.90	0.04	0.50	91.43	No	Yes	No	Yes	Inh.
9o	98.56	−2.27	37.81	0.04	0.57	92.17	No	Yes	No	Yes	Inh.
9p	98.11	−2.14	42.99	0.05	0.05	92.90	No	Yes	No	Yes	Inh.
9q	97.99	−2.10	43.47	0.05	0.03	91.65	No	Yes	No	Yes	Inh.
9r	97.86	−2.05	43.93	0.05	0.03	91.71	No	Yes	No	Yes	Inh.




Figure 4. SAR study of the target compounds 9a-r.

activities with IC_{50} values of 1.37–6.26 μM (cisplatin IC_{50} =6.62 μM). While, moderate cytotoxic activity was noticed for test compounds against colon HT-29 cell line. The most potent derivatives between them were **9a**, **9l**, and **9n** (IC_{50} =2.10–2.37 μM), if compared with cisplatin (IC_{50} =1.12 μM).

The most active derivatives **9a**, **9d**, **9f**, **9n**, and **9r** (either against K-562 and/or MCF-7 cell lines) were selected for further evaluation against human normal fibroblast cells (WI38). All of them had IC_{50} values (29.19–40.13 μM) higher than that of the reference cisplatin (IC_{50} =18.86 μM), except **9a** analogue (IC_{50} =17.09 μM) which was slightly less than cisplatin.

Moreover, STAT3 and STAT5a inhibitory activities were determined for the five later compounds. Compounds **9d** and **9n** showed remarkable inhibitory activity against STAT3, while, compounds **9a**, **9f**, **9n**, and **9r** were the most effective at inhibiting STAT5a. Dual inhibitory activity at STAT3 and STAT5a was observed in compound **9n** which bore *p*-nitrophenyl and *p*-chlorophenyl rings at pyrimidine core in addition to dimethoxyphenyl at chalcone part. On the other hand, physicochemical properties, drug likeness scores, pharmacokinetics and toxicity properties were predicted for all the synthesised compounds **9a-r**.

Acknowledgements

The authors thank Dr. Essam Rashwan, head of the confirmatory diagnostic unit VACSERA-Egypt for evaluation of anticancer activity and enzyme assays.

Disclosure statement

The authors declare that there is no any conflict of interest.

References

- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics. *CA Cancer J Clin* 2015;65:87–108.
- Rao YK, Fang SH, Tzeng YM. Differential effects of synthesized 2'-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution. *Bioorg Med Chem* 2004;12:2679–86.
- Roco A, Quinones L, Acevedo C, et al. Situacion del cancer en Chile 2000–2010. *Cuad Med Social* 2013;53:83–94.
- Rajak H, Deshmukh R, Veerasamy R, et al. Novel semicarbazones based 25-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity. *Bioorg Med Chem Lett* 2010;20:4168–72.
- Marmol I, Sanchez-De-Diego C, Dieste AP, et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. *Int J Mol Sci* 2017;18:E197.
- Stewart B, Wild C. World cancer report 2014. World Health Organization; 2014.
- Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. *Cell* 1991;64:337–50.

8. Gleixner KV, Schneeweiss M, Eisenwort G, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. *Haematologica* 2017;102:1519–29.
9. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. *Leuk Lymphoma* 2002;43:1221–8.
10. Ghiaur G, Wroblewski M, Loges S. Acute myelogenous leukemia and its microenvironment: a molecular conversation. *Semin Hematol* 2015;52:200–6.
11. Bosc C, Selak MA, Sarry J-E. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. *Cell Metab* 2017;26:705–7.
12. Coolbrandt A, Van den Heede K, Vanhove E, et al. Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? *Eur J Oncol Nurs* 2011;15:130–6.
13. McMurray JS, Ren Z, David C, et al. Inhibitors of signal transducer and activator of transcription 3. US 0010428 A1; 2007.
14. Mandal PK, Gao F, Lu Z, et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the src homology 2 (SH2) domain of signal transducer and activator of transcription 3. *J Med Chem* 2011;54:3549–63.
15. Turkson J, Gunning PT. 2-(9h-Purin-9-yl) acetic acid analogues as inhibitors of STAT proteins: University of Central Florida Research Foundation, University of Toronto Mississauga. Patent WO 163424 A2; 2011.
16. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumour activity. *Proc Natl Acad Sci USA* 2007;104:7391–6.
17. Segatto I, Baldassarre G, Belletti B. STAT3 in breast cancer onset and progression: a matter of time and context. *Int J Mol Sci* 2018;19:2818–27.
18. Furqan M, Mukhi N, Lee B, et al. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. *Biomark Res* 2013;1:5–15.
19. Ping-Shan L, David AR, Ahmed MA, et al. A STAT inhibitor patent review: progress since 2011. *Expert Opin Ther Patents* 2015;25:12–37.
20. Furqan M, Akinleye A, Mukhi N, et al. STAT inhibitors for cancer therapy. *J Hematol Oncol* 2013;6:90.
21. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin Cancer Res* 2002;8:945–54.
22. Weaver AM, Silva CM. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. *Breast Cancer Res* 2007;9:R79–89.
23. Jatiani SS, Baker SJ, Silverman LR, et al. JAK/STAT pathways in cytokine signaling and myelo-proliferative disorders: approaches for targeted therapies. *Genes Cancer* 2011;1: 979–93.
24. Fathi MAA, Abd El-Hafeez AA, Abdelhamid D, et al. 1,3,4-Oxadiazole/chalcone hybrids: design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. *Bioorg Chem* 2019;84:150–63.
25. Yu H, Jove R. The STATs of cancer – new molecular targets come of age. *Nat Rev Cancer* 2004;4:97–105.
26. Zhang X, Yue P, Fletcher S, et al. A novel small-molecule disrupts STAT3 SH2 domain-phosphotyrosine interactions and STAT3-dependent tumor processes. *Biochem Pharmacol* 2010;79:1398–409.
27. Li PK, Li C, Lin J, et al. Curcumin analogs as dual JAK2/STAT3 Inhibitors and methods of making and using the same. The Ohio State University Research Foundation. US 0053208 A1; 2012.
28. Novilla A, Mustofa M, Astuti I, et al. Cytotoxic activity of methoxy-4'-amino chalcone derivatives against leukemia cell lines. *Mol Cell Biomed Sci* 2019;3:34–41.
29. Bagul C, Rao GK, Makani VKK, et al. Synthesis and biological evaluation of chalcone linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents. *Med Chem Commun* 2017;8: 1810–6.
30. Page BDG, Khoury H, Laister RC, et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. *J Med Chem* 2012;55:1047–55.
31. Ahmed NM, Mohamed MS. Synthesis and biological value of thiouracils and fused thiouracils (a review). *J Adv Pharm Res* 2017;1:75–88.
32. Prachayasittikul S, Worachartcheewan A, Nantasenamat C, et al. Synthesis and structure activity relationship of 2-thiopyrimidine-4-one analogs as antimicrobial and anticancer agents. *Eur J Med Chem* 2011;46:738–42.
33. Sondhi SM, Goyal RN, Lahoti AM, et al. Synthesis and biological evaluation of 2-thiopyrimidine derivatives. *Bioorg Med Chem* 2005;13:3185–95.
34. Yuh-Wen H, Maw CS. Thioxopyrimidine in heterocyclic synthesis I: synthesis of some novel 6-(heteroatom-substituted)-(thio)pyrimidine derivatives. *J Chem* 2013;1:1–15.
35. Angelo R, Andre S, Silvia S, et al. Synthesis and antiproliferative activity of basic thioanalogues of merbarone. *Bioorg Med Chem* 2003;11:2575–89.
36. Chen H, Tsalkova T, Mei FC, et al. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. *Bioorg Med Chem Lett* 2012;22:4038–43.
37. Oluropo CA, Olugbeminiyi OF, Adamson SF, et al. Synthesis and *in-vitro* cytotoxicity evaluation of some fluorinated hexahydropyrimidine derivatives. *Bioorg Med Chem Lett* 2011; 21:989–92.
38. Mosaad SM, Samir MA, Omar AF, et al. Synthesis of new pyrimidine derivatives and their antiproliferative activity against selected human cancer cell lines. *Res Chem Intermed* 2015; 41:1789–801.
39. Narwal S, Kumar S, Verma PK. Design, synthesis and antimicrobial evaluation of pyrimidin-2-ol/thiol/amine analogues. *Chem Cent J* 2017;11:52–61.
40. Al-Hazam HA, Al-Shamkani ZA, Al-Masoudia NA, et al. New chalcones and thiopyrimidine analogues derived from mefenamic acid: microwave-assisted synthesis, anti-HIV activity and cytotoxicity as antileukemic agents. *Z Naturforsch* 2017;72:1–8.
41. Al-Masoudi NA, Kadhim RA, Abdul-Rida NA, et al. New biaryl-chalcone derivatives of pregnenolone via Suzuki-Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study. *Steroids* 2015;101:43–50.
42. Amor EC, Villasenor IM, Antemano R, et al. Cytotoxic C-methylated chalcones from *Syzygium samarangense*. *Pharm Biol* 2007;45:777–83.
43. Zhang EH, Wang RF, Guo SZ, et al. An update on antitumor activity of naturally occurring chalcones. *J Evid Based Complement Altern Med* 2013;2013:1–22.

44. Peng F, Meng CW, Zhou QM, et al. Cytotoxic evaluation against breast cancer cells of isoliquiritigenin analogues from *Spatholobus suberectus* and their synthetic derivatives. *J Nat Prod* 2016;79:248–51.
45. Ahmed FF, Abd El-Hafeez AA, Abbas SH, et al. New 1,2,4-triazole-chalcone hybrids induce caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells. *Eur J Med Chem* 2018;151:705–22.
46. Lamie PF, Philoppes JN. Design and synthesis of three series of novel antitumor – azo derivatives. *Med Chem Res* 2017; 26:1228–40.
47. Philoppes JN, Lamie PF. Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents. *Bioorg Chem* 2019;89:102978–91.
48. Molinspiration Cheminformatics. Nova ulica, SK-900 26 Slovensky Grob, Slovak Republic. Available from: <http://www.molinspiration.com/>.
49. PreADMET is a web-based application for predicting ADME data and building drug-like library using in silico method. Available from: <https://preadmet.bmdrc.kr/>.
50. Stefani HA, Oliveira CB, Almeida RB, et al. Dihydropyrimidin-(2*H*)-ones obtained by ultrasound irradiation: a new class of potential antioxidant agents. *Eur J Med Chem* 2006;41:513–8.
51. Walters WP, Ajay , Murcko MA. Recognizing molecules with drug-like properties. *Curr Opin Chem Biol* 1999;3:384–7.
52. Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. *Expert Opin Investig Drugs* 2013;22:775–85.